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TREATMENT OF CO-MORBID CHRONIC PAIN AND SUBSTANCE USE 
DISORDERS 
LISA ELLISON 
 
ABSTRACT  
 
 Chronic pain affects approximately 15% of the adult population with substance 
use disorders (SUDS) estimated to co-occur in 15% to 28% of the chronic pain 
population. When these two disorders co-occur, there can be multiple implications for the 
affected individuals as well as numerous complications for treatment. This study 
examined the outcomes and program completion rates of two groups of chronic pain 
SUDS patients who had followed different treatment paths after their admission to the 
Cleveland Clinic’s Chronic Pain Rehabilitation Program (CC-CPRP). Prior to June of 
2009, pre-identified chronic pain SUDS patients were advised to complete a separate 
chemical dependency program before attending the CC-CPRP and/or to attend 12-step 
meetings after their admission to the CC-CPRP. However, as of June 2009, chronic pain 
patients identified with co-morbid SUDS received integrated chronic pain treatment and 
substance use education within a specialized SUDS track of the CC-CPRP. Results from 
these two treatment group comparisons did not indicate significant differences between 
patient outcomes or program completion rates. Potential explanations and limitations are 
explored, as are considerations for future studies.     
 
 
 
 
 
 
 
 v 
 
Table of Contents 
ABSTRACT……………………………………………………………………………iv 
TABLE OF CONTENTS………………………………………………………………v  
LIST OF TABLES……………………………………………………………………..vii                                                                                                                    
CHAPTER 
 
I.  REVIEW OF LITERATURE…………………………………………….1 
 
1.1 Chronic Pain Defined……………………...…………..……1 
 
1.2 Chronic Pain: Effects and Implications…….……………….2 
 
1.3 Substance Use Disorders Defined..…………………………3 
        
1.4 Substance Use Disorders in the Chronic Pain Population.…4 
            
1.5 Chronic Pain and Substance Use Treatment………...……...6 
 
1.6 Cleveland Clinic Chronic Pain Rehabilitation Program..…..8 
 
1.7 Purpose of Study…………….……………………………...10 
 
II. METHODS………………………………………..……………………...12 
 
2.1 Participants………………………………………….……....12 
 
2.2 Measures…………………………………………………….13 
 
2.3 Preliminary Analyses……………………………………......16 
 
2.4 Data Analysis…………………………………………...…...17 
 
III. RESULTS………………………………………………………………….18 
 
   3.1 Chi-Square Analysis…………………………………………18 
 
   3.2 T-Test Analysis…………………………………...…………19 
 
   3.3 Multivariate Analyses of Variances…………………...…….19 
 
  3.4 MANCOVA……………………………………………….....21 
 
  3.5 Logistic Regression…………………………………………..23 
 vi 
 
IV. DISCUSSION…………………………………………………………...24 
 
V. REFERENCES………………………………………………………….68 
 
VI. APPENDIX …………………………………………………………….72  
 
A. Cleveland State IRB Approval…………………...……….72 
 
B. Cleveland Clinic IRB Approval……………………...…...73 
 
C. Depression Anxiety Stress Scale....…………………...….74 
 
D. Pain Disability Index ….………………………………….77 
 
E. Pain Intensity NRS-11 .…………………………………...78 
 vii 
 
LIST OF TABLES 
 
 
Table          Page 
Chi-Square Analyses to identify covariates 
1.  Chi-Square Analysis- Program Enrollment and Gender..........................29 
2. Chi-Square Analysis- Program Enrollment and Ethnicity……………….30 
3. Chi-Square Analysis- Dropout and Gender.……………………………..31 
4. Chi-Square Analysis- Dropout and Ethnicity………………………........32 
T-Test Analyses to identify covariates 
5. T-Test Analysis- Program Enrollment and Age.………………………..33 
6. T-Test Analysis- Dropout and Age.………………………………..…...34 
Multivariate Analysis of Variance (MANOVA) to identify pre-treatment equivalence 
across DASS, NRS-11, and PDI admission scores 
7.  MANOVA………………………………………………………...…...35 
MANOVA’s to identify demographic variables as covariates 
8. Age………….…………………………………………………………..38 
9. Gender…………...……………………………………………………...44 
10. Ethnicity………………….…………………………………………..…53 
11. MANCOVA………………………………………………....................56 
MANOVA for patient outcome comparison at six and twelve months 
12. MANOVA- 6 month scores on DASS, NRS, and PDI…………………60 
13. MANOVA- 12 month scores on DASS, NRS, and PDI……………......63 
Logistic Regression 
14. Logistic Regression……………………………………………..………66
  
1 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I 
 
REVIEW OF THE LITERATURE 
 
 
1.1 Chronic Pain Defined 
Chronic pain is an important and common international health problem estimated 
to affect approximately 15% of the adult population (Manchikanti, Damron, McManus, & 
Barnhill, 2004). The National Institute for Neurological Disorders and Stroke (NINDS, 
2010) defines chronic pain as, “the persistent perception of pain in which pain signals 
continue to fire in the nervous system for long periods of time.” The International 
Association for the Study of Pain (IASP) also describes chronic pain as “pain without 
apparent biological value that has persisted beyond the normal tissue healing time” 
(Clark, Stoller, & Brooner, 2008). People suffering from chronic pain could experience 
their symptoms for years after onset. This differs from acute pain in which pain 
sensations are triggered as the result of a possible injury and last for a relatively short 
time. Acute pain can, however, transform into chronic pain if the pain persists past a 
reasonable recovery time frame for the initial injury as is indicated by the IASP definition 
(NINDS, 2010).  
The World Health Organization has also formed criteria for diagnosing chronic 
pain, which includes that the pain has been present for at least six months, is moderate-to-
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severe in its intensity, and is causing sufficient impairment of functioning such that the 
individual seeks professional or pharmacological help (Clark et al., 2008). Chronic pain 
is commonly viewed as a biopsychosocial phenomenon in which biological, 
psychological, and social aspects are thought to interact and contribute to the condition 
(Dersh, Polatin, & Gatchel, 2002; McAllister, McKenzie, Schultz, & Epsheteyn, 2005). 
There are a variety of causes of chronic pain and its symptoms can result in detrimental 
effects to all aspects of an individual’s life.  
1.2 Chronic Pain Effects and Implications 
Chronic pain has negative, multi-dimensional effects and implications for both the 
affected individual as well as the society in which they live. Research has shown that 
chronic pain can have detrimental effects on daily functioning, work abilities, economic 
status, and physical and psychological wellbeing (Clark et al., 2008; Smith, Elliot, 
Chambers, Cairns Smith, Hannaford, & Penny, 2001; Turk, 2002). Chronic pain sufferers 
frequently report decreases in their daily functioning skills, as well as in their abilities to 
work. When the pain related disabilities in work or daily living begin to increase, the 
physical quality of life tends to decrease for these individuals (Rabini et al., 2007). These 
individuals can face difficulties with work attendance and performance as well problems 
with completing tasks of daily living. This can result in additional stress and 
psychological implications for chronic pain sufferers such as increases in depression or 
anxiety (Clark et al., 2008).    
Other aspects of chronic pain patients’ quality of life, such as their affective 
stability and emotional reserves, can also be disrupted as a result of their chronic pain. 
While the psychological and social effects of chronic pain are difficult to quantify, the 
emotional vulnerability these patients experience in their quest for relief can leave them 
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feeling hopeless, helpless, and even depressed. Chronic pain and its symptoms can also 
affect patients’ social interactions and interpersonal relationships as well. The frequent 
need for assistance and support from family and friends can become taxing to the pre-
existing relationships. Caregivers, spouses, friends, and family can also become frustrated 
by the continued reports of pain despite multiple treatment efforts (Turk, 2002).    
       On a societal level, chronic pain becomes a financial dilemma requiring 
health care expenditures, disability benefits, lost productivity, and use of tax revenues. 
Insurance companies are faced with increasing medical costs and compensation payments 
for their clients affected by chronic pain. These companies also join in the frustration 
shared by the patient and their social supports when the patient remains disabled, and in 
pain, despite all treatment efforts (Turk, 2002). These patients’ disabilities can also 
transcend their home and medical environments into their work environments resulting in 
costly leaves of absence and unemployment (Andersson, 1999).   
Chronic pain also has negative implications in the medical arena. In addition to 
the financial burden on the medical field, chronic pain symptoms can complicate the 
evaluation, diagnosis, and treatment of other medical and psychiatric disorders for these 
individuals (Clark et al., 2008). Research has shown high prevalence rates of diagnosable, 
co-morbid psychopathologies in patients with chronic pain, including depression, anxiety, 
and substance use disorders with the latter being among the most frequent co-morbid 
conditions (Dersh et al., 2002). 
1.3 Substance Use Disorders Defined 
 It is estimated that between 3% and 16% of the American population suffers from 
some form of substance use disorder (Gourlay & Heit, 2008). These substance use 
disorders (SUDS), are commonly categorized into conditions of abuse or dependence. 
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Substance abuse, as defined by the Diagnostic and Statistical Manual of Mental 
Disorders-IV (DSM-IV, American Psychiatric Association, 1994), is a “maladaptive 
pattern of substance abuse leading to clinically significant impairment or distress, as 
manifested by at least one of several criteria” (Dersh et al., 2002). The DSM-IV also 
provides diagnostic criteria for substance dependence which involves both 
psychological/behavioral and physiological dependence. The psychological/behavioral 
criteria focus on substance-seeking activities and pathological use patterns while the 
criterion for physiological dependence emphasizes the body’s physical reactions to 
prolonged substance use such as tolerance and withdrawal. Additionally, the American 
Society of Addiction Medicine developed further criteria for diagnosing addiction in 
chronic pain patients who are being treated with narcotics because it is likely they would 
meet the physiological criteria for dependence as a result of their maintenance medication 
regimen. These diagnostic criteria focus more on the behavioral symptoms of dependence 
such as experiencing adverse consequences as a result of narcotics use or a preoccupation 
with obtaining narcotics (Dersh et al., 2002). A substance use disorder in either category, 
when combined with a chronic pain condition, can result in additional difficulties for the 
treatment of both disorders and likely will require further resources and strategies to 
achieve success.        
1.4 Substance Use Disorders in the Chronic Pain Population 
 Substance use disorders co-occur frequently in the chronic pain population with 
an estimated prevalence rate between 15% and 28% (Caldiero, et al 2008; Dersh et al., 
2002). The symptoms involved with these two conditions frequently interact and result in 
both conditions affecting the treatment process of the other thereby making the 
rehabilitation process much more complex. Research has shown that concurrent 
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substance abuse reduces the likelihood of success of chronic pain treatment. These 
patients are more likely to resist alternative coping strategies and end pain treatment 
early. They may exhibit an over-reliance on, and addiction to, opioid medication which 
can result in resistance to preferred non-pharmacologic treatment options (Currie et al., 
2003).These patients are not open to treatments that emphasize how to live and cope with 
chronic pain and its biological, psychological, and social complications, which are 
preferred approaches to managing chronic pain. Because the overall goal in treating 
chronic pain is to reduce pain while improving functioning, multidisciplinary chronic 
pain programs often include biofeedback training, physical therapy, coping skills 
training, relaxation training, and counseling in addition to medication management to 
reach this goal (Clark et al, 2008; Cleveland Clinic Foundation, n.d.; Gourlay & Heit, 
2008; Krupnick 2009; McAllister et al, 2005; NINDS, 2010; Ziegler, 2005). These 
approaches are designed to assist individuals to learn how pain affects multiple aspects of 
their lives and how they can more effectively cope with and manage these effects. 
However, dually diagnosed patients are more likely to believe that narcotics are more 
effective in relieving pain, improving their mood, and enhancing their abilities to function 
than these alternative treatment approaches (Clark et al., 2008; Krupnick, 2009).  
 An additional complication with dually diagnosed patients is that chronic pain 
symptoms and impairments can exacerbate or complicate substance use symptoms and 
treatment. Chronic pain can increase drug-seeking motivation and drug-taking behavior 
including the use of illicit drugs as these patients, who are often experiencing a decreased 
quality of life, attempt to improve their affect and reduce pain symptoms (Clark et al., 
2008). Another troublesome aspect of these two diagnoses is the etiology of the two 
separate disorders. It is frequently difficult for physicians to determine whether chronic 
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pain patients suffered from SUDS prior to the onset of their chronic pain syndrome, or if 
these patients developed SUDS in response to their pain (Trafton, Oliva, Minkel, & 
Humphreys, 2003). Many of the medications that are used for pain relief, especially upon 
initial diagnosis, can exacerbate or reactivate preexisting SUDS making the knowledge of 
a pre-morbid substance use disorder valuable for guiding treatment (Ziegler, 2005). This 
combination of complicated interactions between symptoms and belief sets involved in 
treating chronic pain patients with SUDS, as well as the ambiguity of disorder etiology, 
creates multiple challenges for the effective management and treatment of these co-
morbid conditions.     
1.5 Chronic Pain and Substance Use Treatment 
It is clear that when chronic pain and substance use disorders (SUDS) co-occur, 
there are multiple challenges involved with treatment. Chronic pain treatment programs 
typically focus on weaning patients off opioids while teaching effective coping strategies 
for living with chronic pain. For chronic pain patients with SUDS in these programs, 
dropout rates are higher and successful outcomes are lower than for their chronic pain 
peers without SUDS. These SUDS patients are also more likely to leave treatment early, 
to be under psychological distress, and to be resistant to learning alternative methods of 
coping skills, all of which pose great challenges for treatment (Currie et al., 2003).  
There are also differing clinical opinions regarding the best treatment for patients 
with SUDS in chronic pain programs (Currie et al., 2003). One approach is to have these 
patients go through treatment sequentially, treating the drug or alcohol use disorder first, 
and then treating the chronic pain. Research has suggested that this sequential treatment 
model has limitations in treating chronic pain SUDS patients because many of these 
patients use substances as an attempt to control their pain and pain-related symptoms. If 
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they have not learned effective coping skills to manage their pain, their risk of relapse 
increases. An alternative approach, known as the integrated model approach, which 
ideally includes a range of pain management techniques such as relaxation training, 
physical therapy, biofeedback, exercise, substance abuse education, relapse prevention, 
and group/individual counseling, is now emerging as the preferred and more effective 
strategy to treating chronic pain patients with and without SUDS (Currie et al., 2003). 
Since there has been little empirical evidence to support the integrated treatment model, 
this emergence is based on the support it has received from professionals working in the 
field as well as the rationale that patients with chronic pain and SUDS need to learn a 
new range of coping skills in order for them to reduce their reliance on substances for the 
relief of chronic pain symptoms (Currie et al., 2003).  
Unfortunately, few published studies to date directly compare these two treatment 
approaches. A meta-analytic study by Flor and colleagues investigated the efficacy of 
integrated treatment versus uni-modal or sequential treatment and found that even at 
long-term follow-up chronic pain patients treated in the integrated program were 
functioning 75% better than their peers who had been treated sequentially demonstrated 
by improvements in measures of the patients’ mood, behavior, and pain ratings (Flor, 
Fydrich, & Turk, 1992; Morley, Eccleston, & Williams, 1999). Findings from another 
meta-analytic study by Turner in 1996 were consistent with these results, with the 
exception that participants in the integrated treatment group did not exhibit a significant 
change in mood. However, this may have been due to the participants’ lacking mood 
related difficulties as they scored low on depression scales at intake (Morley et al, 1999; 
Turner, 1996). Since both studies included meta-analyses, there was not one common 
measure used across studies for patients’ mood, behavior, and pain ratings.  
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A more recent study by McAllister and colleagues included chronic pain 
participants with co-occurring SUDS in their investigation of the efficacy of an 
integrative, multidisciplinary pain program. While this study did not directly compare 
integrated treatment to sequential treatment, results indicated that the integrative model 
significantly reduced opioid medication use, reported pain severity, and healthcare 
utilizations. These data suggest that participation in an integrated pain treatment program 
may effectively improve patients’ symptoms and functioning and may be a cost-effective 
intervention by decreasing healthcare utilization (McAllister et al., 2005). Additionally, 
research on chronic pain and SUDS indicates these are biopsychosocial phenomena that 
would theoretically respond well to an integrative approach that treats the biological, 
psychological, and social components of the disorders in one program (Clark et al, 2008; 
Currie et al, 2003; McAllister et al., 2005).  
1.6 Cleveland Clinic Chronic Pain Rehabilitation Program 
The Cleveland Clinic’s Chronic Pain Rehabilitation Program (CC-CPRP) in 
Cleveland, Ohio is a comprehensive, integrative, interdisciplinary treatment program 
providing specialized care for those suffering from chronic pain. Treatment focuses on 
helping patients regain control of their lives, resume normal functioning and activities, 
overcome depression and anxiety, re-establish interpersonal relationships with family and 
friends, become free of addicting drugs, and develop an overall sense of wellness. To 
reach these goals, treatment services within the CC-CPRP includes physical therapy, 
occupational therapy, psychophysiological pain and stress management , education on 
chronic pain, coping-skills training, medication management and monitored addictive 
medication weaning, vocational evaluations (as needed), and psychotherapy including 
cognitive behavioral therapy. Thus this integrative approach to treatment requires an 
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interdisciplinary team of professionals for pain management, psycho-physiological pain 
and stress management training, nursing, nutrition, psychotherapy, and physical, 
vocational, and occupational therapy who work together to compassionately care for 
patients while helping them to overcome limitations and accomplish their goals 
(Cleveland Clinic Foundation, n.d.).  
Treatment within the CC-CPRP is on a day-care basis and usually lasts three to 
four weeks. It also features a monthly Aftercare Program to help graduates maintain and 
further their progress (Cleveland Clinic Foundation, n.d.). As of June 8, 2009, this 
integrative approach to treatment also includes a specialized substance use disorders 
(SUDS) track within the CC-CPRP that focuses on treating patients with co-morbid 
substance use and chronic pain disorders by offering substance use classes and education 
in conjunction with the chronic pain program. However, prior to June 8, 2009, the CC-
CPRP did not have a specialized SUDS track for patients with concurrent substance use 
and chronic pain. Treatment for these individuals, when identified, followed different 
paths depending on the patients’ initial diagnoses. Prior to being admitted into the CC-
CPRP, all patients were initially screened for signs of substance abuse. Often, if a 
potential patient was identified as having an addiction to alcohol or an illegal substance, 
the patient would be advised to complete a separate chemical dependency program 
through which the substance use disorder could be treated before the patient would be 
admitted to the CC-CPRP. If, based on the initial screening, a patient was identified has 
having an addiction to prescription pain medications, the patient was admitted to the 
program but requested to participate in an appropriate 12-step addiction program as well 
as some group and individual education sessions.  
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Over time, this method proved challenging as patients were not always initially 
forthcoming about their substance use and thus would be admitted to the program only to 
be later identified as a substance abuser. Without prior knowledge that a substance use 
disorder needed to be addressed, and without an established curriculum for addressing the 
needs of these patients within the program, patients with SUDS who were not pre-
identified but were admitted into the CP-CPRP faced additional challenges for treatment 
that were thought to be reducing their likelihood of program completion and overall 
success. Based on the evolving research into pain management and substance use 
disorders such as that discussed above, as well as the experienced difficulties with the 
previous approach, the CC-CPRP developed its integrative treatment model to provide 
more comprehensive education with an established curriculum, with the goal of 
improving the completion rates and outcomes for patients with concurrent substance use 
disorders and chronic pain.          
1.7 Purpose of Study 
Given that chronic pain and substance use disorders co-occur relatively frequently 
with an estimated prevalence rate of 15% to 28% and that research, such as the studies by 
Flor, Turner, and McAllister, are beginning to show that an integrated model of treatment 
may be the more effective strategy for treating chronic pain patients, the CC-CPRP 
attempted to improve the treatment for this population by introducing an integrative 
model approach to the program (Caldiero et al,2008; Flor et al, 1992; McAllister et al., 
2005; Morley et al, 1999; Turner,1996). To do this, the CC-CPRP implemented a SUDS 
track for chronic pain patients identified as having a co-occurring substance use disorder. 
The SUDS track includes substance abuse education and relapse prevention in addition to 
the pain management, biofeedback, coping skills, physical therapy, and group/individual 
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counseling that are offered to all chronic pain patients in the CC-CPRP. This study will 
attempt to add support to the handful of published studies that show improved outcomes 
for chronic pain SUDS patients treated within an integrated model chronic pain program. 
This study utilized archival data derived from the CC-CPRP secured patient 
databases to compare the outcomes and dropout rates of chronic pain patients with SUDS 
prior to and after the implementation of the SUDS track in June of 2009. Based on the 
current review of the literature, it was predicted that the chronic pain patients with SUDS 
who were admitted to the CC-CPRP after the implementation of the SUDS track will 
have significantly better clinical outcomes and lower dropout rates than the chronic pain 
patients with SUDS who were admitted prior to implementation of the integrative 
treatment approach. Patients’ demographic and admissions data were compared between 
the two groups. Then, patient outcomes were measured using patients’ self-reported 
ratings of pain intensity, depression, anxiety, stress, and pain disability while dropout 
rates were determined on the basis of whether or not each client completed the program. 
It was predicted that more chronic pain patients with SUDS will have completed the 
program if they received treatment in the integrative treatment program than those who 
had received treatment sequentially. It was also predicted that the patients from the 
integrative program will have lower pain intensity, depression, anxiety, stress, and pain 
disability ratings at discharge than did those admitted prior to the SUDS track 
implementation.      
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CHAPTER II 
 
METHODS 
 
 
2.1 Participants 
 
 Archival data for the current study were derived from the Cleveland Clinic’s 
Chronic Pain Rehabilitation Program’s (CC-CPRP) database. The data set used for this 
study consists of all patients seen in the Chronic Pain Rehabilitation Program from 2007 
to June 2010 who had a dual diagnosis of a chronic pain disorder and a substance use 
disorder. All patients were 18 years of age or older. Data on the age, race, gender, 
socioeconomic status, marital status, and education level of each patient were included in 
the analyses. Overall, data were collected from 812 patients including both SUDS and 
non-SUDS patients. Of the 521 patients admitted to the CPRP prior to the 
implementation of the SUDS track, 237 patients were identified with SUDS (103 males 
and 134 females). In addition, of the 291 patients admitted after the implementation of 
the SUDS track, 110 patients were identified with SUDS; however, three patients 
declined to transfer into the SUDS track, resulting in a final participant pool of 107 (40 
males and 67 females). Institutional Review Board approval for this research was 
obtained from both Cleveland State University (Appendix A) and the Cleveland Clinic 
Foundation (Appendix B). 
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 The current study also utilized data from the extensive CC-CPRP database that 
includes patients’ diagnoses, pain intensity, cognitive functioning, physical functioning, 
stress levels, mood, and treatment length. These data were collected from all patients 
upon admission, discharge, and six and twelve months after discharge. Depression, 
anxiety, and stress levels were recorded using the Depression, Anxiety, and Stress Scales 
(DASS) while daily functioning was assessed using the Pain Disability Index (PDI) 
(Appendix C and Appendix D). Pain intensity data were collected using the Numerical 
Rating Scale - 11 (NRS-11) for pain (Appendix E). No additional data collection was 
necessary as all data needed for the current study had previously been obtained and stored 
in the CC-CPRP database.   
2.2 Measures 
 
Upon admission and discharge, clinical staff including clinic physicians, 
psychologists, post-doctoral fellows, nurses, nursing assistants, and graduate level 
trainees collected patient information by requesting that patients complete a number of 
self-report assessments. Attempts to collect this patient information via the mail were 
also made at six and twelve months post discharge utilizing these same self-report 
surveys. All information and data collected was then entered and stored into CC-CPRP 
databases on secure computer systems at the Cleveland Clinic Foundation’s Main 
Campus. The current study used data obtained from three of these self-report instruments: 
the Numerical Rating Scale -11 (NRS-11), the Depression, Anxiety, and Stress Scales 
(DASS), and the Pain Disability Index (PDI). 
The Numerical Rating Scale -11 is a pain intensity measure through which 
patients can self- report their current level of pain on a scale of 0-10. Patients rated their 
level of current pain, as well as their typical level of pain, with zero representing “no 
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pain” and ten representing “worst possible pain” (Farrar, Young, LaMoreaux, Werth, & 
Poole, 2001). The NRS-11 has been demonstrated to be a valid and reliable self-report 
measure for assessing patient pain levels. The test-retest reliability of the NRS-11 has 
been examined in multiple studies and found to consistently fall in the moderate to high 
range of reliability varying from .67 to .96 (Kahl & Cleland, 2005). Also, the convergent 
validity of the NRS-11 has been demonstrated to be strong; varying from 0.79 to 0.95 
when compared to a similar common self-report measure of pain, the visual analogue 
scale (Kahl & Cleland, 2005).    
The Depression, Anxiety, and Stress Scales (DASS, Psychology Foundation of 
Australia, 2010) includes three 14-item scales that together comprise a 42-item self-report 
questionnaire designed to identify the presence and severity of core symptoms of 
depression, anxiety, and stress. The Depression scale component of the DASS assesses 
the patient’s reported dysphoria, hopelessness, devaluation of life, self-deprecation, 
anhedonia, and energy level. The Anxiety scale of the DASS is designed to assess the 
patient’s autonomic arousal, skeletal muscle effects, situational anxiety, and subjective 
experiences of anxiousness. The third component, the Stress scale, assesses the client’s 
reported difficulty to relax, extent of nervous arousal, and how easily and frequently the 
client becomes upset/agitated, irritable/over-reactive, and impatient. Clients use a 4-point 
severity/frequency scoring system to rate the extent to which they have experienced any 
of described states over the past week. The scores for each scale, Depression, Anxiety, 
and Stress, are then calculated by totaling the scores of the relevant items from the 
corresponding scale (Psychology Foundation of Australia, 2010).  
The DASS has been tested in both clinical and non-clinical settings and has been 
found to have high internal consistency with alphas ranging from .84-.97 across studies 
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(Anthony, Beilnig, Cox, Enns, & Swinson, 1998; Crawford, & Henry, 2003; Psychology 
Foundation of Australia, 2010). It has also been found to have adequate convergent 
validity when the subscales are compared with other psychometrically sound measures 
such as the Beck Depression Inventory (r=.74) and the Beck Anxiety Inventory (r=.81). 
Internal consistency, an indicator of reliability, for the DASS using Crohnbach’s alpha 
has been demonstrated to be high for each subscale: depression (.91), anxiety (.84), and 
stress (.90) (Crawford & Henry, 2003; Lovibond, & Lovibond, 1995).        
The Pain Disability Index (PDI) is a 7-item self-report measure that assesses the 
degree to which a patient’s chronic pain interferes with his or her various daily activities. 
Each of seven dimensions of daily living activities is assessed by one item:  family/home 
responsibility, recreation, social activity, occupation, sexual behavior, self-care, and life 
support activity. The patients rate each dimension using a 0-10 scale with “0” 
representing “no disability” related to pain and “10” representing “complete disability” 
relating to pain. Patients’ total scores are then derived by summing the score from each 
dimension with totals ranging from zero to seventy (Tait, Pollard, Margolis, Duckro, & 
Krause, 1987).   
The PDI has been shown to have adequate test-retest reliability (intraclass r= .91) 
and to be associated with the pain related behaviors patients actually exhibit (Gronblad et 
al., 1993; Tait, Chibnall, & Krause, 1990). It also has been found to have adequate 
construct validity, a high degree of internal consistency (alpha = .86), and the ability to 
discriminate between patients with low and high levels of disability (Chibnall & Tait, 
1994). Thus, the PDI appears to be a valid and reliable measure of the impact of chronic 
pain on patients’ daily functioning. Dropout rates of these two groups will also be 
compared using data on whether or not the patients completed the program. 
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2.3 Preliminary Analyses 
All data analyses were conducted at the Cleveland Clinic Foundation’s Main 
Campus using the CPRP secured databases. Participants’ were divided into two groups 
based on whether they received sequential treatment (group one) prior to June 8, 2009, or 
whether they received integrated treatment (group two) after June 8, 2009. To assess for 
covariance with program enrollment, separate Chi-Square tests of independence analyses 
were completed for patient gender and ethnicity. A Chi-Square test of independence is a 
statistical analysis that allows researchers to assess for group differences of frequency 
distributions between two observed groups using contingency tables (Aron & Aron, 
2002). In addition, Independent Sample T-Tests were run to determine group equivalence 
on age and to assess for possible covariance with dropout rate. To assess for pre-
treatment equivalence between groups upon admission to the program, a multivariate 
analysis of variance (MANOVA) was conducted using patients’ admission scores on the 
DASS, PDI, and NRS-11. The MANOVA analysis is a commonly used multivariate 
statistical method for determining significance when analyzing data with continuous, 
metric, dependent variables. Analysis with a MANOVA reduces the error rate that a 
researcher may find significance when there actually is not a significant difference by 
allowing the researcher to run one analysis instead of running multiple univariate 
ANOVAS (Hair, Black, Babin, & Anderson, 2010). Multiple separate MANOVA’s were 
also run to assess the demographic variables as potential covariates for each set of scores 
at each of the three time frames (discharge, six month follow-up, and twelve month 
follow-up).   
 
 
 17 
 
2.4 Data Analysis  
 A Logistic Regression analysis was used to test the prediction that the group 
receiving integrated treatment will have significantly fewer dropouts than the group that 
received sequential treatment. Logistic Regression is a statistical analysis that allows the 
researcher to identify the independent variables that effect group membership in the 
dependent variable and can be used when there are categorical dependent variables and 
either metric or non-metric independent variables (Hair, Black, Babin, & Anderson, 
2010). 
The prediction that the integrated program group will have significantly better 
outcomes on the DASS, PDI, and NRS -11 than the sequential treatment group at 
discharge and follow-up was evaluated through a multivariate analysis of covariance 
(MANCOVA) for the discharge scores and a MANOVA for the six and twelve month 
follow-up scores. MANCOVA is a statistical analysis that allows researchers to account 
for any covariates between the groups that may have significant influences on the 
measured outcomes. In the preliminary analyses, patient age and ethnicity were identified 
as co-varying with DASS, NRS-11, and PDI scores at discharge and were subsequently 
included in the MANCOVA analysis as a covariate. No covariates were identified in the 
preliminary analyses at the six and twelve month follow-ups; thus separate MANOVAs 
were used to assess for statistically significant differences in DASS, NRS-11, and PDI 
scores between the two groups after at these times. All statistical analyses were analyzed 
using the Predictive Analytics Software Statistic Data Editor computer software program 
(PASW).   
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CHAPTER III 
 
RESULTS 
 
 
3.1 Chi-Square Analyses 
 
 Two separate Chi-Square analyses were completed to assess patient gender and 
ethnicity for possible covariance with program enrollment. Gender was not found to 
significantly covary with whether or not a patient was enrolled in the program prior to, or 
after, the SUDS track was developed (p=.409; Table 1). Patient ethnicity was divided into 
two categories: white and non-white. Six patients whose ethnicity was unidentified were 
excluded from the analysis leaving data from 234 SUDS patients who had enrolled prior 
to the SUDS track and 103 SUDS patients who had been admitted to the SUDS track to 
be analyzed. As shown in Table 2, there was no significant covariance between patient 
ethnicity and program enrollment (p=.371).    
 Two additional Chi-Square analyses were also conducted to assess patient gender 
and ethnicity for possible covariance with program dropout. Again, gender was not found 
to have a significant covariance with program completion (p=.412; Table 3). Patient 
ethnicity remained divided as white or non-white; as shown in Table 4, patient ethnicity 
co-varied significantly with whether or not a patient dropped out of the program (2[1] = 
9. 830, p=.002) with patients in the non-white group being less likely to complete the 
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program than the patients in the white category. Because patient ethnicity was identified 
as a covariate with program dropout, it was included as a covariate in logistic regression 
analyses 
3.2 T-Test Analyses 
 To assess patient age as a potential covariate for program enrollment or program 
dropout, two T-Test analyses were conducted. As shown in Tables 5 and 6, age was not 
determined to significantly co-varying with program enrollment (p=.981) or with 
program dropout (p=.306).  
3.3 Multivariate Analysis of Variances 
 As shown in Table 7, a MANOVA was conducted to assess for group equivalence 
across DASS, NRS-11, and PDI scores upon admission. While, as indicated by a 
significant Box’s M statistic (.003), the assumption of homogeneity of 
variances/covariances was violated, there were no significant differences in scores 
between the two groups at admission (p=.069). This conclusion should be made with 
caution however as a significant Box’s M statistic indicates heterogeneity of 
variances/covariances which is a violation of the MANOVA assumption that the 
variance/covariances are homogenous and may lead to an inaccurate overall significance 
finding. Non-significant Levene’s tests (p=.069) indicate the inequality is with the 
covariance matrices, not the variance matrices. Covariances were then qualitatively 
assessed to determine possible origins of heterogeneity that may have contributed to the 
significant Box's M. Differences in correlations were noted between the two groups on 
the depression variable with the stress, pain intensity and PDI variables. Additional 
correlation differences were also found between the pain intensity and PDI scores for this 
analysis with all correlation differences being greater than .150.    
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 In addition, a series of MANOVAs was run to assess for covariances between the 
demographic variables and the dependent variables at each time period: discharge, six 
months, and twelve months. As seen in Table 8, patient age was found to significantly co-
vary with discharge scores on the PDI (F(1)= 15.286, p=.000) with pain disability scores 
increasing as age increases. Given these results, age was included, where appropriate, as 
a covariate in subsequent analyses utilizing discharge data. However, patient gender was 
not demonstrated to have significant covariance with any of the dependent variables at 
discharge, six months, or twelve months post program completion (Table 9). However, 
the homogeneity of variances/covariance matrices was violated as indicated by a 
significant Box’s M (p=.000). This violation was further assessed and the Anxiety 
discharge scores were noted to be causing the heterogeneity with the larger group 
(females) having the larger variance and no significant multivariate effects for gender. 
This result increases the likelihood of a Type II error which indicates there may be an 
effect for gender that is undetected. Covariances were also qualitatively assessed to 
determine possible origins of heterogeneity that may have also contributed to the 
significant Box's M. Differences in correlations were noted between the two groups on 
the depression variable with the pain intensity and PDI variables. Additional correlation 
differences were also found between the anxiety scores with stress, pain intensity and 
PDI scores as well as differences between stress and pain intensity correlations. All 
correlation differences were greater than .150 suggesting these correlations contributed to 
the heterogeneity of covariances in this analysis.  
 Additionally, as seen in Table 10, patient ethnicity was also found to significantly 
co-vary with discharge scores on the Depression and Stress scales of the DASS (F(1)= 
6.957,p=.009, F(1)= 12.984, p=.000) as well as the PDI (F(1)= 16.180, p=.000). Again 
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the homogeneity of variance/covariance assumption was violated with patient discharge 
depression scores causing the heterogeneity. The larger group (White) had the smaller 
variance with significant multivariate effects which increases the likelihood of a Type I 
error. However, given the current significant results, patient ethnicity was also included 
as a covariate in subsequent analyses utilizing discharge data. An additional investigation 
of the origins of heterogeneity in this data by qualitatively comparing the correlation 
differences between the variables resulted in significant differences on the depression 
scores with anxiety and pain intensity scores. Correlation differences also occurred on the 
stress variable with the anxiety, pain intensity, and PDI variables as well as the stress 
scores with the pain intensity scores. These correlation differences were all greater than 
.150 which suggests these differences may contribute to the overall heterogeneity of 
covariances in this analysis.   
3.4 Multivariate Analysis of Covariance 
 To test the hypothesis that the group of chronic pain SUDS patients treated within 
the specialized SUDS track would have better outcome successes than the group treated 
prior to this track implementation as indicated by lower scores on the DASS, NRS-11, 
and PDI at discharge, a MANCOVA was conducted. Age and ethnicity were included in 
this analysis as covariates. The results indicate there was a violation of the homogeneity 
assumption of covariance matrices with a significant Box’s M statistic (p=.000) and 
significant Levene’s tests for the Anxiety scale scores of the DASS (p=.006) and the NRS 
– 11 scores (p=.013). These violations were further assessed and it was noted that patient 
discharge anxiety scores and pain intensity ratings were contributing to the heterogeneity 
in the analysis. Patient discharge anxiety scores had larger variances in the smaller group 
(patients in SUDS track) with no significant multivariate effects for program enrollment 
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which indicates this violation does not have any effect on the results. However patient 
pain intensity ratings had larger variances in the larger group with no significant 
multivariate effects which suggests an increased likelihood of a Type I error. However, as 
seen in Table 11, the current results indicate there were no significant differences 
between the two groups scores on the DASS, NRS-11, and PDI at discharge (p=.334). 
Covariances were also qualitatively assessed to determine possible origins of 
heterogeneity that may have also contributed to the significant Box's M. Differences in 
correlations were noted between the two groups on the depression variable with the pain 
intensity and PDI variables. Covariances were also qualitatively assessed to determine 
possible origins of heterogeneity that may have also contributed to the significant Box's 
M. Differences in correlations were noted between the two groups on the depression 
variable with the anxiety and pain intensity variables. Additional correlation differences 
were also found between the anxiety and stress scores as well as differences between 
stress and the pain intensity and PDI variables. These correlation differences were greater 
than .150 suggesting these correlations contributed to the heterogeneity of covariances in 
this analysis.  
 To test the hypotheses that the group treated within the SUDS track would show 
better clinical outcomes at the six and twelve month follow-ups than the group treated 
sequentially as demonstrated by lower scores on the DASS, NRS-11 and PDI, two 
separate MANOVA’s were conducted. However, while there were no assumption 
violations with either analysis, there were also no significant differences noted between 
the groups at six or twelve months post program completion (Table 12 and 13).   
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3.5 Logistic Regression 
 An entry method logistic regression was conducted to test if program 
enrollment determined by whether patients were treated in the integrated SUDS track or 
were treated sequentially in the program could predict patient dropout. Based on the 
results of previous analyses, patient ethnicity was included in the logistic regression as a 
covariate. After controlling for the effects of ethnicity, program enrollment did not 
predict program completion, suggesting there was no significant difference in dropouts 
between the two groups. Table 14 shows the Omnibus Tests of Model Coefficients was 
significant at the .01 level (p= .006). This indicates that patient ethnicity improves the 
predictive power of the null model. Therefore, patient ethnicity is related to the drop 
out/completion rates of SUDS patients who had been admitted to the CC-CPRP. 
However, the Hosmer-Lemeshow test was not significant (p=.887), which indicates 
program enrollment, when accounting for patient ethnicity, is not a statistically 
significant predictor of program completion in the developed logistic regression model. 
The model results shown in the Classification Table of Table 14 indicate that at 95% 
confidence level, the null model correctly predicted program completion 81% of the time. 
The logistic regression model did not improve upon the null model as shown in the 
Variables in the Equation output (p=.148).  
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CHAPTER IV 
DISCUSSION 
  
 The results do not support the hypotheses tested in this research. No significant 
differences in patient outcomes were found between the two SUDS treatment approaches. 
Also, treatment within either program did not successfully predict program completion 
indicating no significant differences between the two groups on program completion or 
dropout. Possible explanations for these findings are discussed below. 
 One possibility for the lack of support for the hypothesis that chronic pain SUDS 
patients treated within the specialized SUDS track would have better outcomes than the 
group treated prior to this track implementation as demonstrated by lower DASS, PDI, 
and NRS-11 scores at discharge and subsequent six and twelve month follow-ups could 
be a function of the CC-CPRP’s commitment and ability to provide the most current and 
innovative treatment options available (Cleveland Clinic, n.d.). It is possible that the 
provision of the highest standard of care within a program of high repute may have had 
greater impact on patient outcomes than the particular treatment regimen the patients 
received. Additionally, relationship variables such as the commitment and support from 
the CC-CPRP professionals may have had a similar beneficial effect on patient drop-out, 
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regardless of the specific program components, resulting in no significant differences in 
program completion between the two groups. 
 One potential limitation to this study is that the patient population came only from 
the CC-CPRP. As previously mentioned, the structure of the program and the high 
standard of professional care may have influenced the overall findings. Future studies 
may want to compare patient groups from multiple chronic pain rehabilitation programs 
that, at some point, made similar changes in their treatment courses for SUDS patients 
with chronic pain or compare “comparable” programs that utilize either a sequential or 
integrative treatment approach. Also, the data from patients treated “sequentially” did 
include those SUDS patients that also attended 12-step meetings during their CC-CPRP 
completion before the SUDS track had been implemented. It was not possible to separate 
those patients from the patients who were referred to chemical dependency treatment 
prior to their completion of the CC-CPRP. Although the attendance of 12-step meetings 
is not as integrated and comprehensive as the current SUDS-track, it may have influenced 
the overall effects of the group. If adjunctive participation in 12-step programs does 
provide benefits to the treatment package, the availability of comparably effective options 
may allow SUDs treatment to be individualized to patients’ needs and preferences; future 
research might investigate whether diagnostic placement into one of several available 
SUDs options increases the completion and success rate relative to automatic placement 
in a sequential or integrated option.  
Another potential limitation to this study was the high rate of missing data, 
particularly at the six and twelve month follow-ups. Of the 273 SUDS patients that 
completed the CC-CPRP, only 71 patients responded to all of the outcome measures at 
six months and only 49 patients responded to all outcome measures at twelve months, 
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which may have contributed to the non-significant findings of this study. Additionally, 
the group of patients treated within the SUDS track (n=107) was less than half the size of 
the group who that been treated sequentially (n=237), as the SUDS track was 
implemented in June of 2009 resulting in only one year of available patient data for the 
SUDS track group at the time of this study. As such, it may be beneficial for future 
researchers to replicate this study once a larger number of patients have completed the 
SUDS track of the CC-CPRP. It is also possible that integrated SUDS treatment may be 
superior to sequential treatment when different dependent variables are assessed. 
Additional possibilities for future research might be patient satisfaction, healthcare 
utilization, opioid use, and substance use both during and after completion of the 
program. Also, future researchers may consider separating out the SUDS patients who 
were transferred into the SUDS track after starting the program and comparing their 
outcomes to the outcomes of patients who were pre-identified and directly admitted to the 
SUDS track. This research combined all SUDS patients who completed the SUDS track, 
however, not all patients were initially admitted into the SUDS track if they had not been 
pre-identified during initial admission screenings.       
 In comparison to the previously mentioned research of Flor and colleagues as well 
as the research by Turner, the current analyses did not include data analysis from any 
previously completed studies. Flor and Turner both used meta-analytic designs to review 
both controlled and uncontrolled studies that had been previously conducted (Flor et al, 
1992; Morley et al, 1999  Turner, 1996). This method increases the reliability of research 
by combining and analyzing results from multiple studies which may have contributed to 
their significant findings. Flor’s meta-analytic review additionally utilized data from over 
a decade ago and since that time; there has been a notable increase in the use of opioids 
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for non-malignant pain (Flor et al, 1992; McAllister, 2005). Thus, the differences in 
population may have contributed to the significant findings from their research and the 
insignificant findings from the current study. Also, in Turner’s research, chronic pain 
patients whose pain was exclusive to headaches or migraines were excluded (Morely et 
al, 1999; Turner 1996). The present study did not exclude data based on type of chronic 
pain condition.  
This study, in comparison to the McAllister study, did have treatment comparison 
groups while McAllister and colleagues did not directly compare two treatment 
approaches. Instead, they investigated the effectiveness of a multidisciplinary chronic 
pain program by comparing the discharge and follow-up data from one group of chronic 
pain patients with their program admission data (McAllister et al, 2005). While the data 
obtained did include pain severity and disability ratings as did the present study, 
McAllister and colleagues (2005) utilized different assessments. Patients in their study 
rated pain severity on a six point Likert scale as opposed to the NRS-11 utilized here. 
Also, pain disability was measured based on the location of patients’ main pain cites by 
utilizing measures such as the Oswestry Back Disability Questionaire, whereas the 
current study assessed all patients’ pain related disability utilizing the same measure. 
Thus while the significant findings of McAllister et al. do provide support for the 
effectiveness of an integrated treatment model, their study was not equivalent in design to 
the current study.                       
 Overall, while the results of this study did not support the original hypotheses, the 
findings nevertheless contribute to the empirical literature on co-morbid SUDS and 
chronic pain treatment approaches by indicating a need for further research to support 
what is now considered to be the preferred treatment approach (Currie et al, 2003). 
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Additionally, considerations for future research have been identified with hopes that 
future studies may account for the limitations encountered with this research.    
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TABLES 
Table 1: Chi-Square of SUDS Patient Program Enrollment x Gender 
Case Processing Summary 
 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
whether or not a SUDS patient was treated within the SUDS 
track * Gender 
344 100.0% 0 .0% 344 100.0% 
 
whether or not a SUDS patient was treated within the SUDS track * Gender Crosstabulation 
 
Gender 
Total Female Male 
whether or not a SUDS 
patient was treated 
within the SUDS track 
SUDS patient enrolled 
prior to SUDS track 
implementation 
Count 134 103 237 
% within whether or not a 
SUDS patient was 
treated within the SUDS 
track 
56.5% 43.5% 100.0% 
SUDS patient enrolled in 
SUDS track 
Count 66 41 107 
% within whether or not a 
SUDS patient was 
treated within the SUDS 
track 
61.7% 38.3% 100.0% 
Total Count 200 144 344 
% within whether or not a 
SUDS patient was 
treated within the SUDS 
track 
58.1% 41.9% 100.0% 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) Exact Sig. (2-sided) Exact Sig. (1-sided) 
Pearson Chi-Square .801
a
 1 .371   
Continuity Correction
b
 .604 1 .437   
Likelihood Ratio .805 1 .370   
Fisher's Exact Test    .409 .219 
Linear-by-Linear Association .799 1 .372   
N of Valid Cases 344     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 44.79. 
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Table 2: Chi-Square of SUDS Patient Program Enrollment x Ethnicity 
Case Processing Summary 
 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
whether or not a SUDS patient was treated within the SUDS 
track * race and ethnicity 
337 100.0% 0 .0% 337 100.0% 
 
whether or not a SUDS patient was treated within the SUDS track * race and ethnicity 
Crosstabulation 
 
race and 
ethnicity 
Total White 
Non-
White 
whether or not a SUDS 
patient was treated 
within the SUDS track 
SUDS patient enrolled 
prior to SUDS track 
implementation 
Count 208 26 234 
% within whether or not a 
SUDS patient was 
treated within the SUDS 
track 
88.9% 11.1% 100.0% 
% of Total 61.7% 7.7% 69.4% 
SUDS patient enrolled in 
SUDS track 
Count 88 15 103 
% within whether or not a 
SUDS patient was 
treated within the SUDS 
track 
85.4% 14.6% 100.0% 
% of Total 26.1% 4.5% 30.6% 
Total Count 296 41 337 
% within whether or not a 
SUDS patient was 
treated within the SUDS 
track 
87.8% 12.2% 100.0% 
% of Total 87.8% 12.2% 100.0% 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) Exact Sig. (2-sided) Exact Sig. (1-sided) 
Pearson Chi-Square .798
a
 1 .372   
Continuity Correction
b
 .507 1 .476   
Likelihood Ratio .775 1 .379   
Fisher's Exact Test    .371 .236 
Linear-by-Linear Association .795 1 .373   
N of Valid Cases 337     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 12.53. 
b. Computed only for a 2x2 table 
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Table 3: Chi-Square of SUDS Patient Dropout x Gender 
Case Processing Summary 
 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
completed the program: * Gender 344 100.0% 0 .0% 344 100.0% 
 
completed the program: * Gender Crosstabulation 
 Gender 
Total Female Male 
completed the program: no Count 42 25 67 
% within completed the program: 62.7% 37.3% 100.0% 
% within Gender 21.0% 17.4% 19.5% 
% of Total 12.2% 7.3% 19.5% 
yes Count 158 119 277 
% within completed the program: 57.0% 43.0% 100.0% 
% within Gender 79.0% 82.6% 80.5% 
% of Total 45.9% 34.6% 80.5% 
Total Count 200 144 344 
% within completed the program: 58.1% 41.9% 100.0% 
% within Gender 100.0% 100.0% 100.0% 
% of Total 58.1% 41.9% 100.0% 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) Exact Sig. (2-sided) Exact Sig. (1-sided) 
Pearson Chi-Square .707
a
 1 .400   
Continuity Correction
b
 .494 1 .482   
Likelihood Ratio .713 1 .398   
Fisher's Exact Test    .412 .242 
Linear-by-Linear Association .705 1 .401   
N of Valid Cases 344     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 28.05. 
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Table 4: Chi-Square of SUDS Patient Dropout X Ethnicity 
Case Processing Summary 
 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
completed the program: * race and ethnicity 337 100.0% 0 .0% 337 100.0% 
 
completed the program: * race and ethnicity Crosstabulation 
 race and ethnicity 
Total White Non-White 
completed the program: no Count 48 15 63 
% within completed the program: 76.2% 23.8% 100.0% 
% of Total 14.2% 4.5% 18.7% 
yes Count 248 26 274 
% within completed the program: 90.5% 9.5% 100.0% 
% of Total 73.6% 7.7% 81.3% 
Total Count 296 41 337 
% within completed the program: 87.8% 12.2% 100.0% 
% of Total 87.8% 12.2% 100.0% 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 9.830
a
 1 .002   
Continuity Correction
b
 8.536 1 .003   
Likelihood Ratio 8.459 1 .004   
Fisher's Exact Test    .004 .003 
Linear-by-Linear 
Association 
9.801 1 .002 
  
N of Valid Cases 337     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 7.66. 
b. Computed only for a 2x2 table 
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Table 5: Group Comparisons of Age and SUDS Program Enrollment using a T-Test 
Group Statistics 
 whether or not a SUDS patient was treated within 
the SUDS track N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Patient's 
Age 
SUDS patient enrolled prior to SUDS track 
implementation 
237 44.35 13.016 .846 
SUDS patient enrolled in SUDS track 107 46.48 12.686 1.226 
 
Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Patient's 
Age 
Equal 
variances 
assumed 
.001 .981 -
1.411 
342 .159 -2.122 1.504 -5.081 .836 
Equal 
variances 
not assumed 
  
-
1.425 
209.458 .156 -2.122 1.490 -5.059 .814 
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Table 6: Group Comparisons of Age and SUDS Patient Program Dropouts 
 
Group Statistics 
 completed the program: N Mean Std. Deviation Std. Error Mean 
Patient's Age 
dimension1 
no 67 45.63 12.293 1.502 
yes 277 44.87 13.101 .787 
 
Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
Patient's 
Age 
Equal 
variances 
assumed 
1.050 .306 .431 342 .666 .760 1.763 -2.707 4.228 
Equal 
variances not 
assumed 
  
.448 105.342 .655 .760 1.696 -2.602 4.122 
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Table 7: MANOVA 
Between-Subjects Factors 
 Value Label N 
 SUDS patient enrolled in 
SUDS track 
41.0155 14.39192 97 
 
Descriptive Statistics 
 whether or not a SUDS patient was 
treated within the SUDS track Mean 
Std. 
Deviation N 
admission total depression SUDS patient enrolled prior to SUDS 
track implementation 
20.12 12.545 169 
SUDS patient enrolled in SUDS track 21.56 12.076 97 
Total 20.65 12.373 266 
admission total anxiety SUDS patient enrolled prior to SUDS 
track implementation 
15.3698 9.58224 169 
SUDS patient enrolled in SUDS track 15.5979 9.40181 97 
Total 15.4530 9.49968 266 
admission total stress SUDS patient enrolled prior to SUDS 
track implementation 
21.2396 10.68517 169 
SUDS patient enrolled in SUDS track 20.9330 12.77033 97 
Total 21.1278 11.46655 266 
Admission pain intensity  (0-10) SUDS patient enrolled prior to SUDS 
track implementation 
6.6331 2.06408 169 
SUDS patient enrolled in SUDS track 6.7732 1.97117 97 
Total 6.6842 2.02808 266 
Admission Total PDI score (sum of 
all PDI domains = 0-70) 
SUDS patient enrolled prior to SUDS 
track implementation 
44.2219 12.90047 169 
SUDS patient enrolled in SUDS track 41.0155 14.39192 97 
Total 43.0526 13.52521 266 
 
Box's Test of Equality of Covariance Matrices
a
 
Box's M 34.922 
F 2.276 
df1 15 
df2 162693.625 
Sig. .003 
Tests the null hypothesis that the observed covariance matrices of the dependent variables are equal 
across groups. 
a. Design: Intercept + Enrolled 
 
Multivariate Tests
c
 
Effect 
Value F 
Hypothesis 
df Error df Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Intercept Pillai's Trace .938 793.171
a
 5.000 260.000 .000 3965.853 1.000 
Wilks' Lambda .062 793.171
a
 5.000 260.000 .000 3965.853 1.000 
Hotelling's 
Trace 
15.253 793.171
a
 5.000 260.000 .000 3965.853 1.000 
Roy's Largest 
Root 
15.253 793.171
a
 5.000 260.000 .000 3965.853 1.000 
Enrolled Pillai's Trace .038 2.078
a
 5.000 260.000 .069 10.391 .686 
Wilks' Lambda .962 2.078
a
 5.000 260.000 .069 10.391 .686 
Hotelling's 
Trace 
.040 2.078
a
 5.000 260.000 .069 10.391 .686 
Roy's Largest 
Root 
.040 2.078
a
 5.000 260.000 .069 10.391 .686 
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a. Exact statistic 
b. Computed using alpha = .05 
c. Design: Intercept + Enrolled 
 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Corrected 
Model 
admission total 
depression 
127.365
a
 1 127.365 .831 .363 .831 .149 
admission total 
anxiety 
3.207
c
 1 3.207 .035 .851 .035 .054 
admission total 
stress 
5.795
d
 1 5.795 .044 .834 .044 .055 
Admission pain 
intensity  (0-10) 
1.209
e
 1 1.209 .293 .589 .293 .084 
Admission Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
633.607
f
 1 633.607 3.496 .063 3.496 .461 
Intercept admission total 
depression 
107092.651 1 107092.651 699.121 .000 699.121 1.000 
admission total 
anxiety 
59101.214 1 59101.214 652.521 .000 652.521 1.000 
admission total 
stress 
109606.995 1 109606.995 830.622 .000 830.622 1.000 
Admission pain 
intensity  (0-10) 
11076.352 1 11076.352 2685.756 .000 2685.756 1.000 
Admission Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
447751.198 1 447751.198 2470.705 .000 2470.705 1.000 
Enrolled admission total 
depression 
127.365 1 127.365 .831 .363 .831 .149 
admission total 
anxiety 
3.207 1 3.207 .035 .851 .035 .054 
admission total 
stress 
5.795 1 5.795 .044 .834 .044 .055 
Admission pain 
intensity  (0-10) 
1.209 1 1.209 .293 .589 .293 .084 
Admission Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
633.607 1 633.607 3.496 .063 3.496 .461 
Error admission total 
depression 
40440.019 264 153.182 
    
admission total 
anxiety 
23911.456 264 90.574 
    
admission total 
stress 
34836.859 264 131.958 
    
Admission pain 
intensity  (0-10) 
1088.765 264 4.124 
    
Admission Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
47843.156 264 181.224 
    
Total admission total 
depression 
153979.250 266 
     
admission total 
anxiety 
87434.250 266 
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admission total 
stress 
153581.000 266 
     
Admission pain 
intensity  (0-10) 
12974.500 266 
     
Admission Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
541515.500 266 
     
Corrected 
Total 
admission total 
depression 
40567.384 265 
     
admission total 
anxiety 
23914.663 265 
     
admission total 
stress 
34842.654 265 
     
Admission pain 
intensity  (0-10) 
1089.974 265 
     
Admission Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
48476.763 265 
     
a. R Squared = .003 (Adjusted R Squared = -.001) 
b. Computed using alpha = .05 
c. R Squared = .000 (Adjusted R Squared = -.004) 
d. R Squared = .000 (Adjusted R Squared = -.004) 
e. R Squared = .001 (Adjusted R Squared = -.003) 
f. R Squared = .013 (Adjusted R Squared = .009) 
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Table 8: MANOVAS for Age and Discharge Dependent Variables 
Descriptive Statistics 
 Mean Std. Deviation N 
discharge total depression 7.43 8.963 246 
discharge total anxiety 7.92 8.748 246 
discharge total stress 9.6870 8.52054 246 
Discharge pain intensity  (0-10) 3.3679 2.48625 246 
Discharge Total PDI score (sum of all PDI 
domains = 0-70) 
18.0447 12.98767 246 
 
Multivariate Tests
c
 
Effect 
Value F 
Hypothesis 
df Error df Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Intercept Pillai's Trace .098 5.229
a
 5.000 240.000 .000 26.143 .987 
Wilks' Lambda .902 5.229
a
 5.000 240.000 .000 26.143 .987 
Hotelling's 
Trace 
.109 5.229
a
 5.000 240.000 .000 26.143 .987 
Roy's Largest 
Root 
.109 5.229
a
 5.000 240.000 .000 26.143 .987 
age Pillai's Trace .061 3.107
a
 5.000 240.000 .010 15.537 .871 
Wilks' Lambda .939 3.107
a
 5.000 240.000 .010 15.537 .871 
Hotelling's 
Trace 
.065 3.107
a
 5.000 240.000 .010 15.537 .871 
Roy's Largest 
Root 
.065 3.107
a
 5.000 240.000 .010 15.537 .871 
a. Exact statistic 
b. Computed using alpha = .05 
c. Design: Intercept + age 
 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Corrected 
Model 
discharge total 
depression 
189.592
a
 1 189.592 2.373 .125 2.373 .335 
discharge total 
anxiety 
85.917
c
 1 85.917 1.123 .290 1.123 .184 
discharge total 
stress 
60.958
d
 1 60.958 .839 .361 .839 .149 
Discharge pain 
intensity  (0-10) 
23.025
e
 1 23.025 3.767 .053 3.767 .489 
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
2436.404
f
 1 2436.404 15.286 .000 15.286 .973 
Intercept discharge total 
depression 
304.116 1 304.116 3.807 .052 3.807 .493 
discharge total 
anxiety 
566.699 1 566.699 7.409 .007 7.409 .774 
discharge total 
stress 
1058.062 1 1058.062 14.564 .000 14.564 .967 
Discharge pain 
intensity  (0-10) 
86.467 1 86.467 14.146 .000 14.146 .963 
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
729.427 1 729.427 4.576 .033 4.576 .568 
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age discharge total 
depression 
189.592 1 189.592 2.373 .125 2.373 .335 
discharge total 
anxiety 
85.917 1 85.917 1.123 .290 1.123 .184 
discharge total 
stress 
60.958 1 60.958 .839 .361 .839 .149 
Discharge pain 
intensity  (0-10) 
23.025 1 23.025 3.767 .053 3.767 .489 
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
2436.404 1 2436.404 15.286 .000 15.286 .973 
Error discharge total 
depression 
19491.913 244 79.885 
    
discharge total 
anxiety 
18661.957 244 76.483 
    
discharge total 
stress 
17725.941 244 72.647 
    
Discharge pain 
intensity  (0-10) 
1491.432 244 6.112 
    
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
38890.104 244 159.386 
    
Total discharge total 
depression 
33257.750 246 
     
discharge total 
anxiety 
34173.500 246 
     
discharge total 
stress 
40871.000 246 
     
Discharge pain 
intensity  (0-10) 
4304.750 246 
     
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
121427.000 246 
     
Corrected 
Total 
discharge total 
depression 
19681.505 245 
     
discharge total 
anxiety 
18747.874 245 
     
discharge total 
stress 
17786.898 245 
     
Discharge pain 
intensity  (0-10) 
1514.456 245 
     
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
41326.508 245 
     
a. R Squared = .010 (Adjusted R Squared = .006) 
b. Computed using alpha = .05 
c. R Squared = .005 (Adjusted R Squared = .001) 
d. R Squared = .003 (Adjusted R Squared = -.001) 
e. R Squared = .015 (Adjusted R Squared = .011) 
f. R Squared = .059 (Adjusted R Squared = .055) 
 
Descriptive Statistics 
 Mean Std. Deviation N 
six month DASS Depression 
total 
12.14 12.696 56 
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six month DASS Anxiety Total 8.97 8.839 56 
six month DASS Stress Total 14.31 11.730 56 
6-month pain intensity level (0-
10) 
4.7768 2.57597 56 
6-month Total PDI score (sum 
of all PDI domains = 0-70) 
26.0179 16.61160 56 
 
Multivariate Tests
c
 
Effect 
Value F 
Hypothesis 
df Error df Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Intercept Pillai's Trace .411 6.986
a
 5.000 50.000 .000 34.932 .997 
Wilks' Lambda .589 6.986
a
 5.000 50.000 .000 34.932 .997 
Hotelling's 
Trace 
.699 6.986
a
 5.000 50.000 .000 34.932 .997 
Roy's Largest 
Root 
.699 6.986
a
 5.000 50.000 .000 34.932 .997 
age Pillai's Trace .137 1.581
a
 5.000 50.000 .183 7.904 .507 
Wilks' Lambda .863 1.581
a
 5.000 50.000 .183 7.904 .507 
Hotelling's 
Trace 
.158 1.581
a
 5.000 50.000 .183 7.904 .507 
Roy's Largest 
Root 
.158 1.581
a
 5.000 50.000 .183 7.904 .507 
a. Exact statistic 
b. Computed using alpha = .05 
c. Design: Intercept + age 
 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Corrected 
Model 
six month DASS 
Depression total 
209.154
a
 1 209.154 1.305 .258 1.305 .202 
six month DASS 
Anxiety Total 
9.002
c
 1 9.002 .113 .738 .113 .063 
six month DASS 
Stress Total 
325.181
d
 1 325.181 2.425 .125 2.425 .334 
6-month pain 
intensity level (0-
10) 
14.014
e
 1 14.014 2.156 .148 2.156 .303 
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
68.537
f
 1 68.537 .245 .623 .245 .077 
Intercept six month DASS 
Depression total 
1458.688 1 1458.688 9.100 .004 9.100 .842 
six month DASS 
Anxiety Total 
433.284 1 433.284 5.456 .023 5.456 .631 
six month DASS 
Stress Total 
2113.029 1 2113.029 15.756 .000 15.756 .974 
6-month pain 
intensity level (0-
10) 
172.905 1 172.905 26.605 .000 26.605 .999 
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
3593.879 1 3593.879 12.845 .001 12.845 .941 
age six month DASS 
Depression total 
209.154 1 209.154 1.305 .258 1.305 .202 
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six month DASS 
Anxiety Total 
9.002 1 9.002 .113 .738 .113 .063 
six month DASS 
Stress Total 
325.181 1 325.181 2.425 .125 2.425 .334 
6-month pain 
intensity level (0-
10) 
14.014 1 14.014 2.156 .148 2.156 .303 
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
68.537 1 68.537 .245 .623 .245 .077 
Error six month DASS 
Depression total 
8655.703 54 160.291 
    
six month DASS 
Anxiety Total 
4288.208 54 79.411 
    
six month DASS 
Stress Total 
7242.100 54 134.113 
    
6-month pain 
intensity level (0-
10) 
350.946 54 6.499 
    
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
15108.445 54 279.786 
    
Total six month DASS 
Depression total 
17122.000 56 
     
six month DASS 
Anxiety Total 
8806.250 56 
     
six month DASS 
Stress Total 
19038.750 56 
     
6-month pain 
intensity level (0-
10) 
1642.750 56 
     
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
53085.000 56 
     
Corrected 
Total 
six month DASS 
Depression total 
8864.857 55 
     
six month DASS 
Anxiety Total 
4297.210 55 
     
six month DASS 
Stress Total 
7567.281 55 
     
6-month pain 
intensity level (0-
10) 
364.960 55 
     
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
15176.982 55 
     
a. R Squared = .024 (Adjusted R Squared = .006) 
b. Computed using alpha = .05 
c. R Squared = .002 (Adjusted R Squared = -.016) 
d. R Squared = .043 (Adjusted R Squared = .025) 
e. R Squared = .038 (Adjusted R Squared = .021) 
f. R Squared = .005 (Adjusted R Squared = -.014) 
 
Descriptive Statistics 
 Mean Std. Deviation N 
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12month DASS Depression total 8.66 9.932 35 
12month DASS Anxiety Total 6.26 6.133 35 
12month DASS Stress Total 9.14 8.671 35 
1-Year pain intensity level (0-10) 4.6857 2.37352 35 
1-Year Total PDI score (sum of all PDI 
domains = 0-70) 
25.8857 17.49583 35 
 
Multivariate Tests
c
 
Effect 
Value F 
Hypothesis 
df Error df Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Intercept Pillai's Trace .331 2.874
a
 5.000 29.000 .032 14.371 .766 
Wilks' Lambda .669 2.874
a
 5.000 29.000 .032 14.371 .766 
Hotelling's 
Trace 
.496 2.874
a
 5.000 29.000 .032 14.371 .766 
Roy's Largest 
Root 
.496 2.874
a
 5.000 29.000 .032 14.371 .766 
age Pillai's Trace .131 .874
a
 5.000 29.000 .511 4.370 .267 
Wilks' Lambda .869 .874
a
 5.000 29.000 .511 4.370 .267 
Hotelling's 
Trace 
.151 .874
a
 5.000 29.000 .511 4.370 .267 
Roy's Largest 
Root 
.151 .874
a
 5.000 29.000 .511 4.370 .267 
a. Exact statistic 
b. Computed using alpha = .05 
c. Design: Intercept + age 
 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Corrected 
Model 
12month DASS 
Depression total 
38.619
a
 1 38.619 .384 .540 .384 .092 
12month DASS 
Anxiety Total 
.129
c
 1 .129 .003 .954 .003 .050 
12month DASS 
Stress Total 
14.008
d
 1 14.008 .182 .673 .182 .070 
1-Year pain 
intensity level (0-
10) 
.209
e
 1 .209 .036 .850 .036 .054 
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
257.042
f
 1 257.042 .836 .367 .836 .144 
Intercept 12month DASS 
Depression total 
414.779 1 414.779 4.129 .050 4.129 .505 
12month DASS 
Anxiety Total 
115.650 1 115.650 2.985 .093 2.985 .389 
12month DASS 
Stress Total 
353.524 1 353.524 4.589 .040 4.589 .548 
1-Year pain 
intensity level (0-
10) 
54.113 1 54.113 9.333 .004 9.333 .843 
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
766.137 1 766.137 2.491 .124 2.491 .335 
age 12month DASS 
Depression total 
38.619 1 38.619 .384 .540 .384 .092 
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12month DASS 
Anxiety Total 
.129 1 .129 .003 .954 .003 .050 
12month DASS 
Stress Total 
14.008 1 14.008 .182 .673 .182 .070 
1-Year pain 
intensity level (0-
10) 
.209 1 .209 .036 .850 .036 .054 
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
257.042 1 257.042 .836 .367 .836 .144 
Error 12month DASS 
Depression total 
3315.266 33 100.463 
    
12month DASS 
Anxiety Total 
1278.557 33 38.744 
    
12month DASS 
Stress Total 
2542.278 33 77.039 
    
1-Year pain 
intensity level (0-
10) 
191.333 33 5.798 
    
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
10150.501 33 307.591 
    
Total 12month DASS 
Depression total 
5977.000 35 
     
12month DASS 
Anxiety Total 
2649.000 35 
     
12month DASS 
Stress Total 
5482.000 35 
     
1-Year pain 
intensity level (0-
10) 
960.000 35 
     
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
33860.000 35 
     
Corrected 
Total 
12month DASS 
Depression total 
3353.886 34 
     
12month DASS 
Anxiety Total 
1278.686 34 
     
12month DASS 
Stress Total 
2556.286 34 
     
1-Year pain 
intensity level (0-
10) 
191.543 34 
     
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
10407.543 34 
     
a. R Squared = .012 (Adjusted R Squared = -.018) 
b. Computed using alpha = .05 
c. R Squared = .000 (Adjusted R Squared = -.030) 
d. R Squared = .005 (Adjusted R Squared= -.025) 
e. R Squared = .001 (Adjusted R Squared = -.029) 
f. R Squared = .025 (Adjusted R Squared = -.005) 
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Table 9: MANOVA for Gender and Discharge Dependent Variables 
Between-Subjects Factors 
 Value Label N 
Gender 0 Female 139 
1 Male 110 
 
Descriptive Statistics 
 Gender Mean Std. Deviation N 
discharge total depression Female 6.92 8.404 139 
Male 7.95 9.563 110 
Total 7.38 8.930 249 
discharge total anxiety Female 8.44 10.071 139 
Male 7.19 6.555 110 
Total 7.89 8.701 249 
discharge total stress Female 9.6799 9.05018 139 
Male 9.6045 7.78233 110 
Total 9.6466 8.49689 249 
Discharge pain intensity  (0-10) Female 3.3201 2.66078 139 
Male 3.4545 2.25806 110 
Total 3.3795 2.48697 249 
Discharge Total PDI score (sum of 
all PDI domains = 0-70) 
Female 17.1223 12.46936 139 
Male 19.3000 13.55556 110 
Total 18.0843 12.97908 249 
 
 
Box's Test of Equality of Covariance Matrices
a
 
Box's M 70.991 
F 4.628 
df1 15 
df2 219169.668 
Sig. .000 
Tests the null hypothesis that the observed covariance matrices of the dependent variables are equal 
across groups. 
a. Design: Intercept + gender 
 
Multivariate Tests
c
 
Effect 
Value F 
Hypothesis 
df Error df Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Intercept Pillai's Trace .746 143.085
a
 5.000 243.000 .000 715.426 1.000 
Wilks' Lambda .254 143.085
a
 5.000 243.000 .000 715.426 1.000 
Hotelling's 
Trace 
2.944 143.085
a
 5.000 243.000 .000 715.426 1.000 
Roy's Largest 
Root 
2.944 143.085
a
 5.000 243.000 .000 715.426 1.000 
gender Pillai's Trace .026 1.312
a
 5.000 243.000 .259 6.561 .461 
Wilks' Lambda .974 1.312
a
 5.000 243.000 .259 6.561 .461 
Hotelling's 
Trace 
.027 1.312
a
 5.000 243.000 .259 6.561 .461 
Roy's Largest 
Root 
.027 1.312
a
 5.000 243.000 .259 6.561 .461 
a. Exact statistic 
b. Computed using alpha = .05 
c. Design: Intercept + gender 
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Levene's Test of Equality of Error Variances
a
 
 F df1 df2 Sig. 
discharge total depression 1.653 1 247 .200 
discharge total anxiety 1.492 1 247 .223 
discharge total stress .793 1 247 .374 
Discharge pain intensity  (0-10) 3.266 1 247 .072 
Discharge Total PDI score (sum of all 
PDI domains = 0-70) 
1.273 1 247 .260 
Tests the null hypothesis that the error variance of the dependent variable is equal across groups. 
a. Design: Intercept + gender 
 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Corrected 
Model 
discharge total 
depression 
64.011
a
 1 64.011 .802 .371 .802 .145 
discharge total 
anxiety 
96.882
c
 1 96.882 1.281 .259 1.281 .204 
discharge total 
stress 
.348
d
 1 .348 .005 .945 .005 .051 
Discharge pain 
intensity  (0-10) 
1.109
e
 1 1.109 .179 .673 .179 .071 
Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
291.208
f
 1 291.208 1.734 .189 1.734 .259 
Intercept discharge total 
depression 
13577.666 1 13577.666 170.120 .000 170.120 1.000 
discharge total 
anxiety 
14998.918 1 14998.918 198.332 .000 198.332 1.000 
discharge total 
stress 
22836.023 1 22836.023 315.032 .000 315.032 1.000 
Discharge pain 
intensity  (0-10) 
2818.298 1 2818.298 454.156 .000 454.156 1.000 
Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
81459.722 1 81459.722 484.996 .000 484.996 1.000 
gender discharge total 
depression 
64.011 1 64.011 .802 .371 .802 .145 
discharge total 
anxiety 
96.882 1 96.882 1.281 .259 1.281 .204 
discharge total 
stress 
.348 1 .348 .005 .945 .005 .051 
Discharge pain 
intensity  (0-10) 
1.109 1 1.109 .179 .673 .179 .071 
Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
291.208 1 291.208 1.734 .189 1.734 .259 
Error discharge total 
depression 
19713.630 247 79.812 
    
discharge total 
anxiety 
18679.469 247 75.625 
    
discharge total 
stress 
17904.551 247 72.488 
    
Discharge pain 
intensity  (0-10) 
1532.776 247 6.206 
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Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
41486.021 247 167.960 
    
Total discharge total 
depression 
33322.750 249 
     
discharge total 
anxiety 
34267.500 249 
     
discharge total 
stress 
41076.000 249 
     
Discharge pain 
intensity  (0-10) 
4377.750 249 
     
Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
123211.000 249 
     
Corrected 
Total 
discharge total 
depression 
19777.641 248 
     
discharge total 
anxiety 
18776.351 248 
     
discharge total 
stress 
17904.900 248 
     
Discharge pain 
intensity  (0-10) 
1533.886 248 
     
Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
41777.229 248 
     
a. R Squared = .003 (Adjusted R Squared = -.001) 
b. Computed using alpha = .05 
c. R Squared = .005 (Adjusted R Squared = .001) 
d. R Squared = .000 (Adjusted R Squared = -.004) 
e. R Squared = .001 (Adjusted R Squared = -.003) 
f. R Squared = .007 (Adjusted R Squared = .003) 
 
 
Between-Subjects Factors 
 Value Label N 
Gender 0 Female 32 
1 Male 24 
 
Descriptive Statistics 
 Gender Mean Std. Deviation N 
six month DASS Depression total Female 11.06 12.733 32 
Male 13.58 12.772 24 
Total 12.14 12.696 56 
six month DASS Anxiety Total Female 8.11 8.299 32 
Male 10.13 9.570 24 
Total 8.97 8.839 56 
six month DASS Stress Total Female 13.63 11.734 32 
Male 15.23 11.913 24 
Total 14.31 11.730 56 
6-month pain intensity level (0-10) Female 4.5781 2.58441 32 
Male 5.0417 2.59563 24 
Total 4.7768 2.57597 56 
6-month Total PDI score (sum of all 
PDI domains = 0-70) 
Female 23.0000 14.32345 32 
Male 30.0417 18.80906 24 
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Descriptive Statistics 
 Gender Mean Std. Deviation N 
six month DASS Depression total Female 11.06 12.733 32 
Male 13.58 12.772 24 
Total 12.14 12.696 56 
six month DASS Anxiety Total Female 8.11 8.299 32 
Male 10.13 9.570 24 
Total 8.97 8.839 56 
six month DASS Stress Total Female 13.63 11.734 32 
Male 15.23 11.913 24 
Total 14.31 11.730 56 
6-month pain intensity level (0-10) Female 4.5781 2.58441 32 
Male 5.0417 2.59563 24 
Total 4.7768 2.57597 56 
6-month Total PDI score (sum of all 
PDI domains = 0-70) 
Female 23.0000 14.32345 32 
Male 30.0417 18.80906 24 
Total 26.0179 16.61160 56 
 
Box's Test of Equality of Covariance Matrices
a
 
Box's M 12.440 
F .744 
df1 15 
df2 9824.922 
Sig. .741 
Tests the null hypothesis that the observed covariance matrices of the dependent variables are equal 
across groups. 
a. Design: Intercept + gender 
 
Multivariate Tests
c
 
Effect 
Value F 
Hypothesis 
df Error df Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Intercept Pillai's Trace .803 40.664
a
 5.000 50.000 .000 203.318 1.000 
Wilks' Lambda .197 40.664
a
 5.000 50.000 .000 203.318 1.000 
Hotelling's 
Trace 
4.066 40.664
a
 5.000 50.000 .000 203.318 1.000 
Roy's Largest 
Root 
4.066 40.664
a
 5.000 50.000 .000 203.318 1.000 
gender Pillai's Trace .070 .752
a
 5.000 50.000 .588 3.762 .248 
Wilks' Lambda .930 .752
a
 5.000 50.000 .588 3.762 .248 
Hotelling's 
Trace 
.075 .752
a
 5.000 50.000 .588 3.762 .248 
Roy's Largest 
Root 
.075 .752
a
 5.000 50.000 .588 3.762 .248 
a. Exact statistic 
b. Computed using alpha = .05 
c. Design: Intercept + gender 
 
Levene's Test of Equality of Error Variances
a
 
 F df1 df2 Sig. 
six month DASS Depression total .005 1 54 .942 
six month DASS Anxiety Total .842 1 54 .363 
six month DASS Stress Total .026 1 54 .872 
6-month pain intensity level (0-10) .088 1 54 .767 
6-month Total PDI score (sum of all 
PDI domains = 0-70) 
2.285 1 54 .136 
Tests the null hypothesis that the error variance of the dependent variable is equal across groups. 
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Levene's Test of Equality of Error Variances
a
 
 F df1 df2 Sig. 
six month DASS Depression total .005 1 54 .942 
six month DASS Anxiety Total .842 1 54 .363 
six month DASS Stress Total .026 1 54 .872 
6-month pain intensity level (0-10) .088 1 54 .767 
6-month Total PDI score (sum of all 
PDI domains = 0-70) 
2.285 1 54 .136 
Tests the null hypothesis that the error variance of the dependent variable is equal across groups. 
a. Design: Intercept + gender 
 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Corrected 
Model 
six month DASS 
Depression total 
87.149
a
 1 87.149 .536 .467 .536 .111 
six month DASS 
Anxiety Total 
55.718
c
 1 55.718 .709 .403 .709 .131 
six month DASS 
Stress Total 
35.292
d
 1 35.292 .253 .617 .253 .078 
6-month pain 
intensity level (0-
10) 
2.947
e
 1 2.947 .440 .510 .440 .100 
6-month Total 
PDI score (sum of 
all PDI domains = 
0-70) 
680.024
f
 1 680.024 2.533 .117 2.533 .346 
Intercept six month DASS 
Depression total 
8330.292 1 8330.292 51.248 .000 51.248 1.000 
six month DASS 
Anxiety Total 
4559.896 1 4559.896 58.054 .000 58.054 1.000 
six month DASS 
Stress Total 
11418.006 1 11418.006 81.860 .000 81.860 1.000 
6-month pain 
intensity level (0-
10) 
1269.125 1 1269.125 189.310 .000 189.310 1.000 
6-month Total 
PDI score (sum of 
all PDI domains = 
0-70) 
38584.024 1 38584.024 143.722 .000 143.722 1.000 
gender six month DASS 
Depression total 
87.149 1 87.149 .536 .467 .536 .111 
six month DASS 
Anxiety Total 
55.718 1 55.718 .709 .403 .709 .131 
six month DASS 
Stress Total 
35.292 1 35.292 .253 .617 .253 .078 
6-month pain 
intensity level (0-
10) 
2.947 1 2.947 .440 .510 .440 .100 
6-month Total 
PDI score (sum of 
all PDI domains = 
0-70) 
680.024 1 680.024 2.533 .117 2.533 .346 
Error six month DASS 
Depression total 
8777.708 54 162.550 
    
six month DASS 
Anxiety Total 
4241.492 54 78.546 
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six month DASS 
Stress Total 
7531.990 54 139.481 
    
6-month pain 
intensity level (0-
10) 
362.013 54 6.704 
    
6-month Total 
PDI score (sum of 
all PDI domains = 
0-70) 
14496.958 54 268.462 
    
Total six month DASS 
Depression total 
17122.000 56 
     
six month DASS 
Anxiety Total 
8806.250 56 
     
six month DASS 
Stress Total 
19038.750 56 
     
6-month pain 
intensity level (0-
10) 
1642.750 56 
     
6-month Total 
PDI score (sum of 
all PDI domains = 
0-70) 
53085.000 56 
     
Corrected 
Total 
six month DASS 
Depression total 
8864.857 55 
     
six month DASS 
Anxiety Total 
4297.210 55 
     
six month DASS 
Stress Total 
7567.281 55 
     
6-month pain 
intensity level (0-
10) 
364.960 55 
     
6-month Total 
PDI score (sum of 
all PDI domains = 
0-70) 
15176.982 55 
     
a. R Squared = .010 (Adjusted R Squared = -.009) 
b. Computed using alpha = .05 
c. R Squared = .013 (Adjusted R Squared = -.005) 
d. R Squared = .005 (Adjusted R Squared = -.014) 
e. R Squared = .008 (Adjusted R Squared = -.010) 
f. R Squared = .045 (Adjusted R Squared = .027) 
 
Between-Subjects Factors 
 Value Label N 
Gender 0 Female 21 
1 Male 15 
 
Descriptive Statistics 
 Gender Mean Std. Deviation N 
12month DASS Depression total Female 9.10 11.519 21 
Male 7.53 7.249 15 
Total 8.44 9.872 36 
12month DASS Anxiety Total Female 6.33 6.777 21 
Male 5.73 5.311 15 
Total 6.08 6.134 36 
12month DASS Stress Total Female 8.00 9.854 21 
Male 10.20 6.742 15 
Total 8.92 8.653 36 
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1-Year pain intensity level (0-10) Female 4.1905 2.67617 21 
Male 5.5333 1.64172 15 
Total 4.7500 2.37096 36 
1-Year Total PDI score (sum of all 
PDI domains = 0-70) 
Female 26.7619 19.04443 21 
Male 26.1000 16.04480 15 
Total 26.4861 17.61634 36 
 
Box's Test of Equality of Covariance Matrices
a
 
Box's M 18.034 
F 1.001 
df1 15 
df2 3633.187 
Sig. .451 
Tests the null hypothesis that the observed covariance matrices of the dependent variables are equal 
across groups. 
a. Design: Intercept + gender 
 
Multivariate Tests
c
 
Effect 
Value F 
Hypothesis 
df Error df Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Intercept Pillai's Trace .832 29.713
a
 5.000 30.000 .000 148.567 1.000 
Wilks' Lambda .168 29.713
a
 5.000 30.000 .000 148.567 1.000 
Hotelling's 
Trace 
4.952 29.713
a
 5.000 30.000 .000 148.567 1.000 
Roy's Largest 
Root 
4.952 29.713
a
 5.000 30.000 .000 148.567 1.000 
gender Pillai's Trace .202 1.520
a
 5.000 30.000 .213 7.599 .458 
Wilks' Lambda .798 1.520
a
 5.000 30.000 .213 7.599 .458 
Hotelling's 
Trace 
.253 1.520
a
 5.000 30.000 .213 7.599 .458 
Roy's Largest 
Root 
.253 1.520
a
 5.000 30.000 .213 7.599 .458 
a. Exact statistic 
b. Computed using alpha = .05 
c. Design: Intercept + gender 
 
Levene's Test of Equality of Error Variances
a
 
 F df1 df2 Sig. 
12month DASS Depression total 1.067 1 34 .309 
12month DASS Anxiety Total .002 1 34 .966 
12month DASS Stress Total .733 1 34 .398 
1-Year pain intensity level (0-10) 4.061 1 34 .052 
1-Year Total PDI score (sum of 
all PDI domains = 0-70) 
.542 1 34 .467 
Tests the null hypothesis that the error variance of the dependent variable is equal across 
groups. 
a. Design: Intercept + gender 
 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Corrected 
Model 
12month DASS 
Depression total 
21.346
a
 1 21.346 .214 .647 .214 .073 
12month DASS 
Anxiety Total 
3.150
c
 1 3.150 .082 .777 .082 .059 
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12month DASS 
Stress Total 
42.350
d
 1 42.350 .558 .460 .558 .112 
1-Year pain 
intensity level (0-
10) 
15.779
e
 1 15.779 2.964 .094 2.964 .387 
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
3.834
f
 1 3.834 .012 .913 .012 .051 
Intercept 12month DASS 
Depression total 
2419.457 1 2419.457 24.269 .000 24.269 .998 
12month DASS 
Anxiety Total 
1274.039 1 1274.039 32.976 .000 32.976 1.000 
12month DASS 
Stress Total 
2898.350 1 2898.350 38.219 .000 38.219 1.000 
1-Year pain 
intensity level (0-
10) 
827.334 1 827.334 155.435 .000 155.435 1.000 
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
24450.834 1 24450.834 76.564 .000 76.564 1.000 
gender 12month DASS 
Depression total 
21.346 1 21.346 .214 .647 .214 .073 
12month DASS 
Anxiety Total 
3.150 1 3.150 .082 .777 .082 .059 
12month DASS 
Stress Total 
42.350 1 42.350 .558 .460 .558 .112 
1-Year pain 
intensity level (0-
10) 
15.779 1 15.779 2.964 .094 2.964 .387 
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
3.834 1 3.834 .012 .913 .012 .051 
Error 12month DASS 
Depression total 
3389.543 34 99.692 
    
12month DASS 
Anxiety Total 
1313.600 34 38.635 
    
12month DASS 
Stress Total 
2578.400 34 75.835 
    
1-Year pain 
intensity level (0-
10) 
180.971 34 5.323 
    
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
10857.910 34 319.350 
    
Total 12month DASS 
Depression total 
5978.000 36 
     
12month DASS 
Anxiety Total 
2649.000 36 
     
12month DASS 
Stress Total 
5483.000 36 
     
1-Year pain 
intensity level (0-
10) 
1009.000 36 
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1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
36116.250 36 
     
Corrected 
Total 
12month DASS 
Depression total 
3410.889 35 
     
12month DASS 
Anxiety Total 
1316.750 35 
     
12month DASS 
Stress Total 
2620.750 35 
     
1-Year pain 
intensity level (0-
10) 
196.750 35 
     
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
10861.743 35 
     
a. R Squared = .006 (Adjusted R Squared = -.023) 
b. Computed using alpha = .05 
c. R Squared = .002 (Adjusted R Squared = -.027) 
d. R Squared = .016 (Adjusted R Squared = -.013) 
e. R Squared = .080 (Adjusted R Squared = .053) 
f. R Squared = .000 (Adjusted R Squared = -.029) 
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Table 10: MANOVA Ethnicity and Discharge Dependent Variables 
Between-Subjects Factors 
 Value Label N 
race and ethnicity .00 White 222 
1.00 Non-White 24 
 
Descriptive Statistics 
 race and ethnicity Mean Std. Deviation N 
discharge total depression 
dimension1 
White 6.94 8.249 222 
Non-White 11.96 13.346 24 
Total 7.43 8.963 246 
discharge total anxiety 
dimension1 
White 7.59 8.629 222 
Non-White 10.94 9.439 24 
Total 7.92 8.748 246 
discharge total stress 
dimension1 
White 9.0586 7.92905 222 
Non-White 15.5000 11.40938 24 
Total 9.6870 8.52054 246 
Discharge pain intensity  (0-10) 
dimension1 
White 3.2905 2.47614 222 
Non-White 4.0833 2.51805 24 
Total 3.3679 2.48625 246 
Discharge Total PDI score (sum 
of all PDI domains = 0-70) dimension1 
White 16.9820 12.49614 222 
Non-White 27.8750 13.58808 24 
Total 18.0447 12.98767 246 
 
Box's Test of Equality of Covariance Matrices
a
 
Box's M 28.543 
F 1.750 
df1 15 
df2 6189.523 
Sig. .036 
Tests the null hypothesis that the observed covariance matrices of the dependent variables are equal 
across groups. 
a. Design: Intercept + ethnicity 
 
Multivariate Tests
c
 
Effect 
Value F 
Hypothesis 
df Error df Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Intercept Pillai's Trace .616 77.150
a
 5.000 240.000 .000 385.749 1.000 
Wilks' Lambda .384 77.150
a
 5.000 240.000 .000 385.749 1.000 
Hotelling's 
Trace 
1.607 77.150
a
 5.000 240.000 .000 385.749 1.000 
Roy's Largest 
Root 
1.607 77.150
a
 5.000 240.000 .000 385.749 1.000 
ethnicity Pillai's Trace .094 4.968
a
 5.000 240.000 .000 24.839 .982 
Wilks' Lambda .906 4.968
a
 5.000 240.000 .000 24.839 .982 
Hotelling's 
Trace 
.103 4.968
a
 5.000 240.000 .000 24.839 .982 
Roy's Largest 
Root 
.103 4.968
a
 5.000 240.000 .000 24.839 .982 
a. Exact statistic 
b. Computed using alpha = .05 
c. Design: Intercept + ethnicity 
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Levene's Test of Equality of Error Variances
a
 
 F df1 df2 Sig. 
discharge total depression 13.943 1 244 .000 
discharge total anxiety 2.913 1 244 .089 
discharge total stress 5.991 1 244 .015 
Discharge pain intensity  (0-10) .158 1 244 .691 
Discharge Total PDI score (sum of all 
PDI domains = 0-70) 
.976 1 244 .324 
Tests the null hypothesis that the error variance of the dependent variable is equal across groups. 
a. Design: Intercept + ethnicity 
 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Corrected 
Model 
discharge total 
depression 
545.618
a
 1 545.618 6.957 .009 6.957 .748 
discharge total 
anxiety 
242.361
c
 1 242.361 3.196 .075 3.196 .429 
discharge total 
stress 
898.660
d
 1 898.660 12.984 .000 12.984 .948 
Discharge pain 
intensity  (0-10) 
13.613
e
 1 13.613 2.213 .138 2.213 .317 
Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
2569.955
f
 1 2569.955 16.180 .000 16.180 .980 
Intercept discharge total 
depression 
7734.618 1 7734.618 98.623 .000 98.623 1.000 
discharge total 
anxiety 
7436.568 1 7436.568 98.053 .000 98.053 1.000 
discharge total 
stress 
13062.757 1 13062.757 188.730 .000 188.730 1.000 
Discharge pain 
intensity  (0-10) 
1177.662 1 1177.662 191.459 .000 191.459 1.000 
Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
43580.199 1 43580.199 274.368 .000 274.368 1.000 
ethnicity discharge total 
depression 
545.618 1 545.618 6.957 .009 6.957 .748 
discharge total 
anxiety 
242.361 1 242.361 3.196 .075 3.196 .429 
discharge total 
stress 
898.660 1 898.660 12.984 .000 12.984 .948 
Discharge pain 
intensity  (0-10) 
13.613 1 13.613 2.213 .138 2.213 .317 
Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
2569.955 1 2569.955 16.180 .000 16.180 .980 
Error discharge total 
depression 
19135.887 244 78.426 
    
discharge total 
anxiety 
18505.513 244 75.842 
    
discharge total 
stress 
16888.239 244 69.214 
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Discharge pain 
intensity  (0-10) 
1500.843 244 6.151 
    
Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
38756.553 244 158.838 
    
Total discharge total 
depression 
33257.750 246 
     
discharge total 
anxiety 
34173.500 246 
     
discharge total 
stress 
40871.000 246 
     
Discharge pain 
intensity  (0-10) 
4304.750 246 
     
Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
121427.000 246 
     
Corrected 
Total 
discharge total 
depression 
19681.505 245 
     
discharge total 
anxiety 
18747.874 245 
     
discharge total 
stress 
17786.898 245 
     
Discharge pain 
intensity  (0-10) 
1514.456 245 
     
Discharge Total 
PDI score (sum 
of all PDI 
domains = 0-70) 
41326.508 245 
     
a. R Squared = .028 (Adjusted R Squared = .024) 
b. Computed using alpha = .05 
c. R Squared = .013 (Adjusted R Squared = .009) 
d. R Squared = .051 (Adjusted R Squared = .047) 
e. R Squared = .009 (Adjusted R Squared = .005) 
f. R Squared = .062 (Adjusted R Squared = .058) 
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Table 11: MANCOVA 
Between-Subjects Factors 
 Value Label N 
whether or not a SUDS patient was treated 
within the SUDS track 
1.00 SUDS patient enrolled 
prior to SUDS track 
implementation 
176 
2.00 SUDS patient enrolled in 
SUDS track 
70 
 
Descriptive Statistics 
 whether or not a SUDS 
patient was treated within the 
SUDS track Mean Std. Deviation N 
discharge total depression SUDS patient enrolled prior 
to SUDS track 
implementation 
7.41 8.667 176 
SUDS patient enrolled in 
SUDS track 
7.48 9.732 70 
Total 7.43 8.963 246 
discharge total anxiety SUDS patient enrolled prior 
to SUDS track 
implementation 
7.33 6.659 176 
SUDS patient enrolled in 
SUDS track 
9.40 12.495 70 
Total 7.92 8.748 246 
discharge total stress SUDS patient enrolled prior 
to SUDS track 
implementation 
9.6761 8.36764 176 
SUDS patient enrolled in 
SUDS track 
9.7143 8.95543 70 
Total 9.6870 8.52054 246 
Discharge pain intensity  (0-
10) 
SUDS patient enrolled prior 
to SUDS track 
implementation 
3.3580 2.62836 176 
SUDS patient enrolled in 
SUDS track 
3.3929 2.10399 70 
Total 3.3679 2.48625 246 
Discharge Total PDI score 
(sum of all PDI domains = 0-
70) 
SUDS patient enrolled prior 
to SUDS track 
implementation 
18.0852 13.37454 176 
SUDS patient enrolled in 
SUDS track 
17.9429 12.05168 70 
Total 18.0447 12.98767 246 
 
Box's Test of Equality of Covariance Matrices
a
 
Box's M 139.272 
F 9.017 
df1 15 
df2 72628.409 
Sig. .000 
Tests the null hypothesis that the observed covariance matrices of the dependent variables are equal 
across groups. 
a. Design: Intercept + age + ethnicity + Enrolled 
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Multivariate Tests
c
 
Effect 
Value F 
Hypothesis 
df Error df Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Intercept Pillai's Trace .098 5.154
a
 5.000 238.000 .000 25.772 .985 
Wilks' Lambda .902 5.154
a
 5.000 238.000 .000 25.772 .985 
Hotelling's 
Trace 
.108 5.154
a
 5.000 238.000 .000 25.772 .985 
Roy's Largest 
Root 
.108 5.154
a
 5.000 238.000 .000 25.772 .985 
age Pillai's Trace .055 2.756
a
 5.000 238.000 .019 13.779 .822 
Wilks' Lambda .945 2.756
a
 5.000 238.000 .019 13.779 .822 
Hotelling's 
Trace 
.058 2.756
a
 5.000 238.000 .019 13.779 .822 
Roy's Largest 
Root 
.058 2.756
a
 5.000 238.000 .019 13.779 .822 
ethnicity Pillai's Trace .089 4.654
a
 5.000 238.000 .000 23.268 .974 
Wilks' Lambda .911 4.654
a
 5.000 238.000 .000 23.268 .974 
Hotelling's 
Trace 
.098 4.654
a
 5.000 238.000 .000 23.268 .974 
Roy's Largest 
Root 
.098 4.654
a
 5.000 238.000 .000 23.268 .974 
Enrolled Pillai's Trace .024 1.152
a
 5.000 238.000 .334 5.758 .407 
Wilks' Lambda .976 1.152
a
 5.000 238.000 .334 5.758 .407 
Hotelling's 
Trace 
.024 1.152
a
 5.000 238.000 .334 5.758 .407 
Roy's Largest 
Root 
.024 1.152
a
 5.000 238.000 .334 5.758 .407 
a. Exact statistic 
b. Computed using alpha = .05 
c. Design: Intercept + age + ethnicity + Enrolled 
 
Levene's Test of Equality of Error Variances
a
 
 F df1 df2 Sig. 
discharge total depression .668 1 244 .415 
discharge total anxiety 7.618 1 244 .006 
discharge total stress .313 1 244 .576 
Discharge pain intensity  (0-10) 6.318 1 244 .013 
Discharge Total PDI score (sum of all 
PDI domains = 0-70) 
1.471 1 244 .226 
Tests the null hypothesis that the error variance of the dependent variable is equal across groups. 
a. Design: Intercept + age + ethnicity + Enrolled 
 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Corrected 
Model 
discharge total 
depression 
682.922
a
 3 227.641 2.900 .036 8.699 .687 
discharge total 
anxiety 
471.367
c
 3 157.122 2.080 .103 6.241 .529 
discharge total 
stress 
927.146
d
 3 309.049 4.436 .005 13.308 .873 
Discharge pain 
intensity  (0-10) 
33.642
e
 3 11.214 1.833 .142 5.498 .473 
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Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
4630.408
f
 3 1543.469 10.179 .000 30.536 .998 
Intercept discharge total 
depression 
280.214 1 280.214 3.569 .060 3.569 .469 
discharge total 
anxiety 
685.466 1 685.466 9.076 .003 9.076 .851 
discharge total 
stress 
993.443 1 993.443 14.260 .000 14.260 .964 
Discharge pain 
intensity  (0-10) 
81.224 1 81.224 13.274 .000 13.274 .952 
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
618.985 1 618.985 4.082 .044 4.082 .521 
age discharge total 
depression 
136.201 1 136.201 1.735 .189 1.735 .259 
discharge total 
anxiety 
42.525 1 42.525 .563 .454 .563 .116 
discharge total 
stress 
25.563 1 25.563 .367 .545 .367 .093 
Discharge pain 
intensity  (0-10) 
20.030 1 20.030 3.273 .072 3.273 .437 
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
2041.458 1 2041.458 13.463 .000 13.463 .955 
ethnicity discharge total 
depression 
492.551 1 492.551 6.274 .013 6.274 .704 
discharge total 
anxiety 
195.049 1 195.049 2.583 .109 2.583 .360 
discharge total 
stress 
865.929 1 865.929 12.429 .001 12.429 .940 
Discharge pain 
intensity  (0-10) 
10.564 1 10.564 1.726 .190 1.726 .258 
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
2158.634 1 2158.634 14.236 .000 14.236 .964 
Enrolled discharge total 
depression 
4.572 1 4.572 .058 .810 .058 .057 
discharge total 
anxiety 
168.616 1 168.616 2.233 .136 2.233 .319 
discharge total 
stress 
4.733 1 4.733 .068 .795 .068 .058 
Discharge pain 
intensity  (0-10) 
.172 1 .172 .028 .867 .028 .053 
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
73.443 1 73.443 .484 .487 .484 .107 
Error discharge total 
depression 
18998.583 242 78.507 
    
discharge total 
anxiety 
18276.507 242 75.523 
    
discharge total 
stress 
16859.753 242 69.668 
    
Discharge pain 
intensity  (0-10) 
1480.814 242 6.119 
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Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
36696.100 242 151.637 
    
Total discharge total 
depression 
33257.750 246 
     
discharge total 
anxiety 
34173.500 246 
     
discharge total 
stress 
40871.000 246 
     
Discharge pain 
intensity  (0-10) 
4304.750 246 
     
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
121427.000 246 
     
Corrected 
Total 
discharge total 
depression 
19681.505 245 
     
discharge total 
anxiety 
18747.874 245 
     
discharge total 
stress 
17786.898 245 
     
Discharge pain 
intensity  (0-10) 
1514.456 245 
     
Discharge Total 
PDI score (sum of 
all PDI domains = 
0-70) 
41326.508 245 
     
a. R Squared = .035 (Adjusted R Squared = .023) 
b. Computed using alpha = .05 
c. R Squared = .025 (Adjusted R Squared = .013) 
d. R Squared = .052 (Adjusted R Squared = .040) 
e. R Squared = .022 (Adjusted R Squared = .010) 
f. R Squared = .112 (Adjusted R Squared = .101) 
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Table 12: MANOVA Six Months 
Between-Subjects Factors 
 Value Label N 
whether or not a SUDS patient was treated 
within the SUDS track 
1.00 SUDS patient enrolled 
prior to SUDS track 
implementation 
14 
2.00 SUDS patient enrolled in 
SUDS track 
42 
 
Descriptive Statistics 
 whether or not a SUDS 
patient was treated within the 
SUDS track Mean Std. Deviation N 
six month DASS Depression 
total 
SUDS patient enrolled prior 
to SUDS track 
implementation 
17.21 14.973 14 
SUDS patient enrolled in 
SUDS track 
10.45 11.551 42 
Total 12.14 12.696 56 
six month DASS Anxiety 
Total 
SUDS patient enrolled prior 
to SUDS track 
implementation 
11.25 9.061 14 
SUDS patient enrolled in 
SUDS track 
8.21 8.742 42 
Total 8.97 8.839 56 
six month DASS Stress Total SUDS patient enrolled prior 
to SUDS track 
implementation 
16.04 11.986 14 
SUDS patient enrolled in 
SUDS track 
13.74 11.733 42 
Total 14.31 11.730 56 
6-month pain intensity level 
(0-10) 
SUDS patient enrolled prior 
to SUDS track 
implementation 
5.8214 2.05321 14 
SUDS patient enrolled in 
SUDS track 
4.4286 2.65856 42 
Total 4.7768 2.57597 56 
6-month Total PDI score 
(sum of all PDI domains = 0-
70) 
SUDS patient enrolled prior 
to SUDS track 
implementation 
36.0714 13.94199 14 
SUDS patient enrolled in 
SUDS track 
22.6667 16.20248 42 
Total 26.0179 16.61160 56 
 
Box's Test of Equality of Covariance Matrices
a
 
Box's M 13.915 
F .785 
df1 15 
df2 2386.282 
Sig. .695 
Tests the null hypothesis that the observed covariance matrices of the dependent variables are equal 
across groups. 
a. Design: Intercept + Enrolled 
 
Multivariate Tests
c
 
Effect 
Value F 
Hypothesis 
df Error df Sig. 
Noncent. 
Parameter 
Observed 
Power
b
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Intercept Pillai's Trace .781 35.719
a
 5.000 50.000 .000 178.595 1.000 
Wilks' Lambda .219 35.719
a
 5.000 50.000 .000 178.595 1.000 
Hotelling's 
Trace 
3.572 35.719
a
 5.000 50.000 .000 178.595 1.000 
Roy's Largest 
Root 
3.572 35.719
a
 5.000 50.000 .000 178.595 1.000 
Enrolled Pillai's Trace .157 1.868
a
 5.000 50.000 .117 9.338 .587 
Wilks' Lambda .843 1.868
a
 5.000 50.000 .117 9.338 .587 
Hotelling's 
Trace 
.187 1.868
a
 5.000 50.000 .117 9.338 .587 
Roy's Largest 
Root 
.187 1.868
a
 5.000 50.000 .117 9.338 .587 
a. Exact statistic 
b. Computed using alpha = .05 
c. Design: Intercept + Enrolled 
 
Levene's Test of Equality of Error Variances
a
 
 F df1 df2 Sig. 
six month DASS Depression total 1.703 1 54 .197 
six month DASS Anxiety Total .000 1 54 .999 
six month DASS Stress Total .061 1 54 .806 
6-month pain intensity level (0-10) 4.692 1 54 .035 
6-month Total PDI score (sum of all 
PDI domains = 0-70) 
.839 1 54 .364 
Tests the null hypothesis that the error variance of the dependent variable is equal across groups. 
a. Design: Intercept + Enrolled 
 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Corrected 
Model 
six month DASS 
Depression total 
480.095
a
 1 480.095 3.092 .084 3.092 .408 
six month DASS 
Anxiety Total 
96.763
c
 1 96.763 1.244 .270 1.244 .195 
six month DASS 
Stress Total 
55.430
d
 1 55.430 .398 .531 .398 .095 
6-month pain 
intensity level (0-
10) 
20.371
e
 1 20.371 3.192 .080 3.192 .419 
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
1886.720
f
 1 1886.720 7.666 .008 7.666 .776 
Intercept six month DASS 
Depression total 
8037.167 1 8037.167 51.761 .000 51.761 1.000 
six month DASS 
Anxiety Total 
3978.013 1 3978.013 51.140 .000 51.140 1.000 
six month DASS 
Stress Total 
9308.037 1 9308.037 66.912 .000 66.912 1.000 
6-month pain 
intensity level (0-
10) 
1103.156 1 1103.156 172.874 .000 172.874 1.000 
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
36226.720 1 36226.720 147.194 .000 147.194 1.000 
Enrolled six month DASS 
Depression total 
480.095 1 480.095 3.092 .084 3.092 .408 
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six month DASS 
Anxiety Total 
96.763 1 96.763 1.244 .270 1.244 .195 
six month DASS 
Stress Total 
55.430 1 55.430 .398 .531 .398 .095 
6-month pain 
intensity level (0-
10) 
20.371 1 20.371 3.192 .080 3.192 .419 
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
1886.720 1 1886.720 7.666 .008 7.666 .776 
Error six month DASS 
Depression total 
8384.762 54 155.273 
    
six month DASS 
Anxiety Total 
4200.446 54 77.786 
    
six month DASS 
Stress Total 
7511.851 54 139.108 
    
6-month pain 
intensity level (0-
10) 
344.589 54 6.381 
    
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
13290.262 54 246.116 
    
Total six month DASS 
Depression total 
17122.000 56 
     
six month DASS 
Anxiety Total 
8806.250 56 
     
six month DASS 
Stress Total 
19038.750 56 
     
6-month pain 
intensity level (0-
10) 
1642.750 56 
     
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
53085.000 56 
     
Corrected 
Total 
six month DASS 
Depression total 
8864.857 55 
     
six month DASS 
Anxiety Total 
4297.210 55 
     
six month DASS 
Stress Total 
7567.281 55 
     
6-month pain 
intensity level (0-
10) 
364.960 55 
     
6-month Total PDI 
score (sum of all 
PDI domains = 0-
70) 
15176.982 55 
     
a. R Squared = .054 (Adjusted R Squared = .037) 
b. Computed using alpha = .05 
c. R Squared = .023 (Adjusted R Squared = .004) 
d. R Squared = .007 (Adjusted R Squared = -.011) 
e. R Squared = .056 (Adjusted R Squared = .038) 
f. R Squared = .124 (Adjusted R Squared = .108) 
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Table 13: MANOVA 12 Months 
Between-Subjects Factors 
 Value Label N 
whether or not a SUDS patient was treated 
within the SUDS track 
1.00 SUDS patient enrolled 
prior to SUDS track 
implementation 
20 
2.00 SUDS patient enrolled in 
SUDS track 
15 
 
Descriptive Statistics 
 whether or not a SUDS 
patient was treated within the 
SUDS track Mean Std. Deviation N 
12month DASS Depression 
total 
SUDS patient enrolled prior 
to SUDS track 
implementation 
8.75 11.711 20 
SUDS patient enrolled in 
SUDS track 
8.53 7.308 15 
Total 8.66 9.932 35 
12month DASS Anxiety Total SUDS patient enrolled prior 
to SUDS track 
implementation 
6.05 6.962 20 
SUDS patient enrolled in 
SUDS track 
6.53 5.041 15 
Total 6.26 6.133 35 
12month DASS Stress Total SUDS patient enrolled prior 
to SUDS track 
implementation 
9.90 9.575 20 
SUDS patient enrolled in 
SUDS track 
8.13 7.501 15 
Total 9.14 8.671 35 
1-Year pain intensity level (0-
10) 
SUDS patient enrolled prior 
to SUDS track 
implementation 
4.8500 1.98083 20 
SUDS patient enrolled in 
SUDS track 
4.4667 2.87518 15 
Total 4.6857 2.37352 35 
1-Year Total PDI score (sum 
of all PDI domains = 0-70) 
SUDS patient enrolled prior 
to SUDS track 
implementation 
24.7500 18.47010 20 
SUDS patient enrolled in 
SUDS track 
27.4000 16.61669 15 
Total 25.8857 17.49583 35 
 
Box's Test of Equality of Covariance Matrices
a
 
Box's M 16.579 
F .916 
df1 15 
df2 3640.800 
Sig. .545 
Tests the null hypothesis that the observed covariance matrices of the dependent variables are equal 
across groups. 
a. Design: Intercept + Enrolled 
 
Multivariate Tests
c
 
Effect 
Value F 
Hypothesis 
df Error df Sig. 
Noncent. 
Parameter 
Observed 
Power
b
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Intercept Pillai's Trace .812 25.124
a
 5.000 29.000 .000 125.622 1.000 
Wilks' Lambda .188 25.124
a
 5.000 29.000 .000 125.622 1.000 
Hotelling's 
Trace 
4.332 25.124
a
 5.000 29.000 .000 125.622 1.000 
Roy's Largest 
Root 
4.332 25.124
a
 5.000 29.000 .000 125.622 1.000 
Enrolled Pillai's Trace .069 .431
a
 5.000 29.000 .823 2.155 .145 
Wilks' Lambda .931 .431
a
 5.000 29.000 .823 2.155 .145 
Hotelling's 
Trace 
.074 .431
a
 5.000 29.000 .823 2.155 .145 
Roy's Largest 
Root 
.074 .431
a
 5.000 29.000 .823 2.155 .145 
a. Exact statistic 
b. Computed using alpha = .05 
c. Design: Intercept + Enrolled 
 
Levene's Test of Equality of Error Variances
a
 
 F df1 df2 Sig. 
12month DASS Depression total 1.315 1 33 .260 
12month DASS Anxiety Total .099 1 33 .755 
12month DASS Stress Total .163 1 33 .689 
1-Year pain intensity level (0-10) 3.081 1 33 .088 
1-Year Total PDI score (sum of all PDI 
domains = 0-70) 
.458 1 33 .503 
Tests the null hypothesis that the error variance of the dependent variable is equal across groups. 
a. Design: Intercept + Enrolled 
 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Noncent. 
Parameter 
Observed 
Power
b
 
Corrected 
Model 
12month DASS 
Depression total 
.402
a
 1 .402 .004 .950 .004 .050 
12month DASS 
Anxiety Total 
2.002
c
 1 2.002 .052 .821 .052 .056 
12month DASS 
Stress Total 
26.752
d
 1 26.752 .349 .559 .349 .088 
1-Year pain 
intensity level (0-
10) 
1.260
e
 1 1.260 .218 .643 .218 .074 
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
60.193
f
 1 60.193 .192 .664 .192 .071 
Intercept 12month DASS 
Depression total 
2560.402 1 2560.402 25.196 .000 25.196 .998 
12month DASS 
Anxiety Total 
1357.202 1 1357.202 35.081 .000 35.081 1.000 
12month DASS 
Stress Total 
2787.438 1 2787.438 36.365 .000 36.365 1.000 
1-Year pain 
intensity level (0-
10) 
744.002 1 744.002 129.029 .000 129.029 1.000 
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
23311.050 1 23311.050 74.344 .000 74.344 1.000 
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Enrolled 12month DASS 
Depression total 
.402 1 .402 .004 .950 .004 .050 
12month DASS 
Anxiety Total 
2.002 1 2.002 .052 .821 .052 .056 
12month DASS 
Stress Total 
26.752 1 26.752 .349 .559 .349 .088 
1-Year pain 
intensity level (0-
10) 
1.260 1 1.260 .218 .643 .218 .074 
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
60.193 1 60.193 .192 .664 .192 .071 
Error 12month DASS 
Depression total 
3353.483 33 101.621 
    
12month DASS 
Anxiety Total 
1276.683 33 38.687 
    
12month DASS 
Stress Total 
2529.533 33 76.653 
    
1-Year pain 
intensity level (0-
10) 
190.283 33 5.766 
    
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
10347.350 33 313.556 
    
Total 12month DASS 
Depression total 
5977.000 35 
     
12month DASS 
Anxiety Total 
2649.000 35 
     
12month DASS 
Stress Total 
5482.000 35 
     
1-Year pain 
intensity level (0-
10) 
960.000 35 
     
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
33860.000 35 
     
Corrected 
Total 
12month DASS 
Depression total 
3353.886 34 
     
12month DASS 
Anxiety Total 
1278.686 34 
     
12month DASS 
Stress Total 
2556.286 34 
     
1-Year pain 
intensity level (0-
10) 
191.543 34 
     
1-Year Total PDI 
score (sum of all 
PDI domains = 0-
70) 
10407.543 34 
     
a. R Squared = .000 (Adjusted R Squared = -.030) 
b. Computed using alpha = .05 
c. R Squared = .002 (Adjusted R Squared = -.029) 
d. R Squared = .010 (Adjusted R Squared = -.020) 
e. R Squared = .007 (Adjusted R Squared = -.024) 
f. R Squared = .006 (Adjusted R Squared = -.024) 
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Table 14: Logistic Regression 
Case Processing Summary 
Unweighted Cases
a
 N Percent 
Selected Cases Included in Analysis 337 100.0 
Missing Cases 0 .0 
Total 337 100.0 
Unselected Cases 0 .0 
Total 337 100.0 
a. If weight is in effect, see classification table for the total number of cases. 
 
Dependent Variable Encoding 
Original Value Internal Value 
dimension0 
no 0 
yes 1 
 
Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) 
race and ethnicity White 296 1.000 
Non-White 41 .000 
whether or not a SUDS patient 
was treated within the SUDS 
track 
SUDS patient enrolled prior to 
SUDS track implementation 
233 1.000 
SUDS patient enrolled in SUDS 
track 
104 .000 
 
Block 0: Beginning Block 
 
Classification Table
a,b
 
 Observed Predicted 
 completed the program: 
Percentage 
Correct  no yes 
Step 0 completed the program: no 0 64 .0 
yes 0 273 100.0 
Overall Percentage   81.0 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant 1.451 .139 109.094 1 .000 4.266 
 
Variables not in the Equation 
 Score df Sig. 
Step 0 Variables Enrolled(1) 2.491 1 .115 
ethnicity(1) 9.393 1 .002 
Overall Statistics 11.462 2 .003 
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Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 10.175 2 .006 
Block 10.175 2 .006 
Model 10.175 2 .006 
 
Model Summary 
Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 317.453
a
 .030 .048 
a. Estimation terminated at iteration number 4 because parameter estimates changed by less than .001. 
 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 .020 1 .887 
 
Contingency Table for Hosmer and Lemeshow Test 
 
completed the program: = no completed the program: = yes 
Total Observed Expected Observed Expected 
Step 1 1 15 15.000 26 26.000 41 
2 19 18.565 70 70.435 89 
3 30 30.435 177 176.565 207 
 
Classification Table
a
 
 Observed Predicted 
 completed the program: 
Percentage 
Correct  no yes 
Step 1 completed the program: no 0 64 .0 
yes 0 273 100.0 
Overall Percentage   81.0 
a. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1
a
 Enrolled(1) .425 .293 2.097 1 .148 1.529 
ethnicity(1) 1.047 .362 8.384 1 .004 2.850 
Constant .286 .372 .592 1 .442 1.331 
a. Variable(s) entered on step 1: Enrolled, ethnicity. 
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Appendix C: Depression Anxiety Stress Scales (DASS) 
DAS S Name: Date: 
Please read each statement and circle a number 0, 1, 2 or 3 that indicates how much the 
statement applied to you over the past week.  There are no right or wrong answers.  Do not spend 
too much time on any statement. 
The rating scale is as follows: 
0  Did not apply to me at all 
1  Applied to me to some degree, or some of the time 
2  Applied to me to a considerable degree, or a good part of time 
3  Applied to me very much, or most of the time 
 
1 I found myself getting upset by quite trivial things 0      1      2      3 
2 I was aware of dryness of my mouth 0      1      2      3 
3 I couldn't seem to experience any positive feeling at all 0      1      2      3 
4 I experienced breathing difficulty (eg, excessively rapid breathing, 
breathlessness in the absence of physical exertion) 
0      1      2      3 
5 I just couldn't seem to get going 0      1      2      3 
6 I tended to over-react to situations 0      1      2      3 
7 I had a feeling of shakiness (eg, legs going to give way) 0      1      2      3 
8 I found it difficult to relax 0      1      2      3 
9 I found myself in situations that made me so anxious I was most 
relieved when they ended 
0      1      2      3 
10 I felt that I had nothing to look forward to 0      1      2      3 
11 I found myself getting upset rather easily 0      1      2      3 
12 I felt that I was using a lot of nervous energy 0      1      2      3 
13 I felt sad and depressed 0      1      2      3 
14 I found myself getting impatient when I was delayed in any way 
(eg, elevators, traffic lights, being kept waiting) 
0      1      2      3 
15 I had a feeling of faintness 0      1      2      3 
16 I felt that I had lost interest in just about everything 0      1      2      3 
17 I felt I wasn't worth much as a person 0      1      2      3 
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18 I felt that I was rather touchy 0      1      2      3 
19 I perspired noticeably (eg, hands sweaty) in the absence of high 
temperatures or physical exertion 
0      1      2      3 
20 I felt scared without any good reason 0      1      2      3 
21 I felt that life wasn't worthwhile 0      1      2      3 
 
 Please turn the page  
 
Reminder of rating scale: 
0  Did not apply to me at all 
1  Applied to me to some degree, or some of the time 
2  Applied to me to a considerable degree, or a good part of time 
3  Applied to me very much, or most of the time 
 
22 I found it hard to wind down 0      1      2      3 
23 I had difficulty in swallowing 0      1      2      3 
24 I couldn't seem to get any enjoyment out of the things I did 0      1      2      3 
25 I was aware of the action of my heart in the absence of physical 
exertion (eg, sense of heart rate increase, heart missing a beat) 
0      1      2      3 
26 I felt down-hearted and blue 0      1      2      3 
27 I found that I was very irritable 0      1      2      3 
28 I felt I was close to panic 0      1      2      3 
29 I found it hard to calm down after something upset me 0      1      2      3 
30 I feared that I would be "thrown" by some trivial but 
unfamiliar task 
0      1      2      3 
31 I was unable to become enthusiastic about anything 0      1      2      3 
32 I found it difficult to tolerate interruptions to what I was doing 0      1      2      3 
33 I was in a state of nervous tension 0      1      2      3 
34 I felt I was pretty worthless 0      1      2      3 
35 I was intolerant of anything that kept me from getting on with 
what I was doing 
0      1      2      3 
36 I felt terrified 0      1      2      3 
37 I could see nothing in the future to be hopeful about 0      1      2      3 
38 I felt that life was meaningless 0      1      2      3 
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39 I found myself getting agitated 0      1      2      3 
40 I was worried about situations in which I might panic and make 
a fool of myself 
0      1      2      3 
41 I experienced trembling (eg, in the hands) 0      1      2      3 
42 I found it difficult to work up the initiative to do things 0      1      2      3 
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Appendix D: Pain Disability Index (PDI) 
Pain Disability Index Sheet 
 
Pain Disability Index: The rating scales below are designed to measure the 
degree to which aspects of your life are disrupted by chronic pain. In other words, we 
would like to know how much pain is preventing you from doing what you would normally 
do or from doing it as well as you normally would. Respond to each category indicating 
the overall impact of pain in your life, not just when pain is at its worst.  
For each of the 7 categories of life activity listed, please circle the number on the 
scale that describes the level of disability you typically experience. A score of 0 means no 
disability at all, and a score of 10 signifies that all of the activities in which you would 
normally be involved have been totally disrupted or prevented by your pain.  
 
Family/Home Responsibilities: This category refers to activities of the home or family. It 
includes chores or duties performed around the house (e.g. yard work) and errands or favors for 
other family members (e.g. driving the children to school).  
No Disability 0__. 1__. 2__. 3__. 4__. 5__. 6__. 7 __. 8__. 9__. 10__. Worst Disability  
 
Recreation: This disability includes hobbies, sports, and other similar leisure time activities.  
No Disability 0__. 1__. 2__. 3__. 4__. 5__. 6__. 7 __. 8__. 9__. 10__. Worst Disability  
 
Social Activity: This category refers to activities, which involve participation with friends and 
acquaintances other than family members. It includes parties, theater, concerts, dining out, and 
other social functions.  
No Disability 0__. 1__. 2__. 3__. 4__. 5__. 6__. 7 __. 8__. 9__. 10__. Worst Disability  
 
Occupation: This category refers to activities that are part of or directly related to one’s job. This 
includes non-paying jobs as well, such as that of a housewife or volunteer.  
No Disability 0__. 1__. 2__. 3__. 4__. 5__. 6__. 7 __. 8__. 9__. 10__. Worst Disability  
 
Sexual Behavior: This category refers to the frequency and quality of one’s sex life.  
No Disability 0__. 1__. 2__. 3__. 4__. 5__. 6__. 7 __. 8__. 9__. 10__. Worst Disability  
 
Self Care: This category includes activities, which involve personal maintenance and 
independent daily living (e.g. taking a shower, driving, getting dressed, etc.)  
No Disability 0__. 1__. 2__. 3__. 4__. 5__. 6__. 7 __. 8__. 9__. 10__. Worst Disability  
 
Life-Support Activities: This category refers to basic life supporting behaviors such as eating, 
sleeping and breathing.  
No Disability 0__. 1__. 2__. 3__. 4__. 5__. 6__. 7 __. 8__. 9__. 10__. Worst Disability  
 
 
Signature_________________________ Please Print______________________  
Date ____________ 
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Appendix E: Pain Intensity NRS-11 
Please rate your current level of pain on a scale of 0 to 10.  
0        1        2        3        4        5        6        7        8        9        10 
0-No pain                      
10- The worst possible pain you can imagine 
 
